NT-3 expression from engineered olfactory ensheathing glia	1
NT-3 expression	1
engineered olfactory ensheathing glia	22
spinal sparing and regeneration	69
Marc J. Ruitenberg ,1,2,3 Dane B. Levison	102
,1 Seok Voon Lee ,1 Joost Verhaagen ,3 Alan R. Harvey1 ,2	142
Giles W. Plant1 ,2 Summary Adenoviral -LRB- AdV -RRB- vectors	201
Giles W. Plant1 ,2	201
Summary Adenoviral -LRB- AdV -RRB- vectors	220
AdV	240
neurotrophin-3 -LRB- AdVNT -	262
neurotrophin-3	262
AdVNT	278
or	288
the bacterial marker	291
enzyme betta-galactosidase -LRB- LacZ gene -RRB-	312
enzyme betta-galactosidase	312
LacZ gene	340
olfactory ensheathing glia	374
-LRB- OEG -RRB- cultures	401
OEG	402
AdV vector-transduced OEG	417
high levels of recombinant neurotrophin	453
high levels	453
recombinant neurotrophin	468
in situ hybridization and enzyme-linked immunosorbent assay techniques	505
in situ hybridization	505
hybridization	513
enzyme-linked immunosorbent assay techniques	531
The biological activity of vector-derived NT-3	577
The biological activity	577
vector-derived NT-3	604
a dorsal root ganglia neurite outgrowth assay	642
Engineered cell suspensions	689
adult Fischer 344	741
rat spinal cord immediately after unilateral cervical -LRB- C4 -RRB-	759
rat spinal cord	759
unilateral cervical -LRB- C4 -RRB-	793
CST	839
animals	870
a total of 200 000 cells	887
a total	887
200 000 cells	898
nontransduced OEG or OEG	920
AdV vectors	961
NT-3 or LacZ	982
3 months after injury	1013
3 months	1013
injury	1028
lesion volumes	1036
all OEG-transplanted rats	1081
control	1126
-LRB- medium-injected -RRB- rats	1134
Anterograde tracing of the lesioned CST projection	1158
Anterograde	1158
the lesioned CST projection	1181
the contralateral sensorimotor cortex	1227
a significantly greater number of distal CST axons	1273
a significantly greater number	1273
distal CST axons	1307
OEG-NT-3	1332
transplanted rats	1342
Behavioural analysis	1361
all rats using open field locomotion scoring	1399
all rats	1399
open field locomotion scoring	1414
a forelimb reaching task with Eshkol -- Wachman movement notation	1449
a forelimb reaching task with Eshkol	1449
a forelimb	1449
task	1469
Eshkol	1479
Wachman movement notation	1486
Wachman	1486
movement notation	1494
Analysis of behavioural tests	1513
Analysis	1513
behavioural tests	1525
no significant differences	1552
recovery between experimental groups	1582
recovery	1582
experimental groups	1599
movement analysis	1629
possible compensatory mechanisms	1662
OEG implantation	1716
The results	1734
OEG transplantation	1763
tissue sparing	1802
injury	1823
appropriate genetic modification	1842
these olfactory-derived cells	1876
long-distance maintenance/regeneration of lesioned adult CST axons	1945
long-distance maintenance/regeneration	1945
lesioned adult CST axons	1987
Introduction The adult mammalian spinal cord	2014
Introduction	2014
The adult mammalian spinal cord	2027
axons	2092
injury	2104
part	2115
the growthinhibiting properties of the mature CNS	2127
the growthinhibiting properties	2127
the mature CNS	2162
Axonal regrowth within the spinal cord	2178
Axonal regrowth	2178
the spinal cord	2201
a certain extent	2250
the inhibitory microenvironment of the CNS , e.g.	2279
the inhibitory microenvironment	2279
the CNS	2314
neural cell transplantation	2332
olfactoryensheathing glia -LRB- OEG -RRB-	2368
olfactoryensheathing glia	2368
OEG	2395
the olfactory nerve layer	2442
the olfactory bulb	2471
e.g. Ramon-Cueto et al. , 1998 ; Yan et al. , 2001 ; Plant et al. , 2003	2491
e.g. Ramon-Cueto et al.	2491
1998 ; Yan et al. , 2001 ; Plant et al.	2516
1998	2516
Yan et al. , 2001 ; Plant et al.	2522
Yan	2522
et al. , 2001 ; Plant et al.	2526
et al. , 2001	2526
et al.	2526
2001	2534
Plant et al.	2540
Plant	2540
et al.	2546
2003	2554
Previous studies	2561
a proportion of severed spinal cord axons	2601
a proportion	2601
spinal cord axons	2625
the presence	2670
OEG	2686
Ramon-Cueto and Nieto-Sampedro , 1994	2691
Ramon-Cueto and Nieto-Sampedro	2691
1994	2723
Li et al. , 1997 , 1998 , 2003	2729
Li	2729
et al. , 1997 , 1998 , 2003	2732
et al.	2732
1997	2740
1998	2746
2003	2752
Ramon-Cueto et al.	2758
Ramon-Cueto	2758
et al.	2770
1998 , 2000 ; Lu et al.	2778
1998 , 2000	2778
1998	2778
2000	2784
Lu et al.	2790
Lu	2790
et al.	2793
2001 , 2002	2801
2001	2801
2002	2807
Takami et al. , 2002	2813
Takami	2813
et al. , 2002	2820
et al.	2820
2002	2828
Keyvan-Fouladi et al. , 2003	2834
Keyvan-Fouladi	2834
et al. , 2003	2849
et al.	2849
2003	2857
Plant et al. , 2003	2863
Plant	2863
et al. , 2003	2869
et al.	2869
2003	2877
Chuah et al. , 2004	2883
Chuah	2883
et al. , 2004	2889
et al.	2889
2004	2897
Ramer et al. , 2004	2903
Ramer	2903
et al. , 2004	2909
et al.	2909
2004	2917
Primary OEG	2924
several trophic factors	2957
Ramon-Cueto and Avila , 1998 ; Boruch et al. , 2001 ; Woodhall et al. , 2001	2982
Ramon-Cueto and Avila	2982
Ramon-Cueto	2982
Avila	2998
1998 ; Boruch et al.	3005
1998	3005
Boruch et al.	3011
Boruch	3011
et al.	3018
2001 ; Woodhall et al. , 2001	3026
2001	3026
Woodhall et al. , 2001	3032
Woodhall	3032
et al. , 2001	3041
et al.	3041
2001	3049
their growth-permissive properties	3080
Trophic factors secreted by OEG	3116
Trophic factors	3116
OEG	3144
nerve growth factor	3156
neurotrophin-4 / 5 and neuregulin	3177
neurotrophin-4	3177
5 and neuregulin	3192
5	3192
neuregulin	3198
Thompson	3210
et al. , 2000 ; Boruch et al. , 2001	3219
et al.	3219
2000 ; Boruch et al.	3227
2000	3227
Boruch et al.	3233
Boruch	3233
et al.	3240
2001	3248
Brain-derived neurotrophic factor	3255
small amounts	3309
neurotrophin-3 -LRB- NT-3 -RRB-	3328
neurotrophin-3	3328
NT-3	3344
detectable quantities -LRB- Boruch et al. , 2001 ; Woodhall et al. , 2001 -RRB-	3370
detectable quantities	3370
Boruch	3393
et al. , 2001 ; Woodhall et al. , 2001	3400
et al.	3400
2001 ; Woodhall et al.	3408
2001	3408
Woodhall et al.	3414
Woodhall	3414
et al.	3423
2001	3431
NT-3	3451
the regrowth of important motor pathways	3487
the regrowth	3487
important motor pathways	3503
spinal cord injuries	3534
particular the corticospinal tract -LRB- CST -RRB-	3559
particular the corticospinal tract	3559
CST	3595
combination with other factors	3611
combination	3611
other factors	3628
a single injection	3659
Schnell et al. , 1994 ; Grill et al. , 1997 ; Blits et al. , 2000	3679
Schnell	3679
et al. , 1994 ; Grill et al. , 1997 ; Blits et al. , 2000	3687
et al. , 1994	3687
et al.	3687
1994	3695
Grill et al. , 1997	3701
Grill	3701
et al. , 1997	3707
et al.	3707
1997	3715
Blits et al. , 2000	3721
Blits	3721
et al. , 2000	3727
et al.	3727
2000	3735
Adult CST neurons	3742
the high affinity receptor for NT	3768
the high affinity receptor	3768
NT	3799
3	3803
TrkC -LRB- Giehl and Tetzlaff , 1996 -RRB-	3806
TrkC	3806
Giehl and Tetzlaff , 1996	3812
Giehl	3812
Tetzlaff , 1996	3822
Tetzlaff	3822
1996	3832
injury -LRB- Liebl et al. , 2001 -RRB-	3877
injury	3877
Liebl	3885
et al. , 2001	3891
et al.	3891
2001	3899
this neurotrophin	3912
a critical factor in CST growth and plasticity	3944
a critical factor	3944
CST growth and plasticity	3965
CST growth	3965
plasticity	3980
It	3992
us -LRB- Ruitenberg et al. , 2003 -RRB- and others -LRB- Cao et al. , 2004 -RRB-	4017
us	4017
Ruitenberg	4021
et al. , 2003	4032
et al.	4032
2003	4040
others	4050
Cao	4058
et al. , 2004	4062
et al.	4062
2004	4070
genetic engineering of OEG	4081
genetic engineering	4081
OEG	4104
a cell type that is more effective in promoting spinal cord repair	4122
a cell type	4122
spinal cord repair	4170
Our previous study	4190
injury and regeneration	4220
the rubrospinal tract -LRB- Ruitenberg et al. , 2003 -RRB-	4247
the rubrospinal tract	4247
Ruitenberg	4270
et al. , 2003	4281
et al.	4281
2003	4289
the present study	4299
the specific aim	4323
an environment	4353
CST regrowth	4386
injury	4405
we	4413
adult OEG	4427
NT-3	4448
an ex vivo adenoviral -LRB- AdV -RRB- vector transduction technique	4459
ex vivo adenoviral -LRB- AdV -RRB-	4462
ex vivo adenoviral	4462
ex vivo	4462
AdV	4482
Ruitenberg	4518
et al. , 2002a	4529
et al.	4529
2002a	4537
These modified OEG	4545
the injured rat cervical spinal cord	4590
the injured rat	4590
cervical spinal cord	4606
a unilateral CST lesion	4633
We	4658
the novel approach	4666
left and right CST projections	4705
different biotin dextran labels	4742
us	4789
the interplay of lesioned	4818
the interplay	4818
intact descending axonal tracts in control and OEGtransplanted rats	4851
intact descending axonal tracts	4851
control and OEGtransplanted rats	4886
Behavioural analysis	4920
a 3 month time period	4959
open field locomotion -LRB- Basso et al. , 1995 -RRB-	4987
open field locomotion	4987
Basso	5010
et al. , 1995	5016
et al.	5016
1995	5024
pellet retrieval -LRB- Thallmair et al. , 1998 -RRB-	5031
pellet retrieval	5031
Thallmair	5049
et al. , 1998	5059
et al.	5059
1998	5067
movement analysis	5077
Whishaw	5096
et al. , 1993	5104
et al.	5104
1993	5112
Material and methods Animals Adult female Fischer 344 rats	5120
Material and methods Animals	5120
Adult female Fischer 344 rats	5149
120	5180
150 g ; Animal Resource Center , Australia	5184
150 g	5184
Animal Resource Center , Australia	5191
the in vivo study of spinal cord injury	5240
study of spinal cord injury	5252
study	5252
spinal cord injury	5261
analysis of the behaviour resulting from such an injury	5284
analysis	5284
the behaviour resulting from such an injury	5296
the behaviour	5296
such an injury	5325
All experimental procedures	5341
National Health and Medical Research Council guidelines -LRB- Australia -RRB-	5382
National Health and Medical Research Council guidelines	5382
Australia	5439
The University of Western Australia Animal Ethics Committee	5471
The University	5471
Western Australia Animal Ethics Committee	5489
Rats	5532
90 % of normal body weight	5556
90 %	5556
normal body weight	5563
amounts of food each day	5608
amounts	5608
food each day	5619
food	5619
each day	5624
This	5634
a constant appetite	5653
the animals	5681
the food pellet retrieval task -LRB- Whishaw and Pellis , 1990 -RRB-	5719
the food pellet retrieval task	5719
Whishaw and Pellis , 1990	5751
Whishaw	5751
Pellis , 1990	5763
Pellis	5763
1990	5771
29 rats	5789
behaviour analysis for 2 weeks prior to surgery	5814
behaviour analysis	5814
2 weeks prior to surgery	5837
2 weeks	5837
surgery	5854
two	5863
the task	5888
the experiment	5920
The remaining 27 animals	5936
surgery	5971
the end of the pre-training period	5982
the end	5982
the pre-training period	5993
2 weeks	6034
recovery	6042
post-injury behavioural testing	6058
Analysis of forelimb function using the forelimb reaching task	6091
Analysis	6091
forelimb function using the forelimb reaching task	6103
forelimb function	6103
the forelimb	6127
task	6149
three times	6173
a week	6185
10 weeks , before the animals were sacrificed for histological analysis	6208
10 weeks	6208
the animals	6225
histological analysis	6257
OEG cultures from adult rat OEG	6280
OEG cultures	6280
adult rat OEG	6298
the olfactory bulb nerve layer	6332
adult female Fischer 344 rats -LRB- 8 weeks old , 200 g ; n = 5 -RRB-	6366
adult female Fischer 344 rats	6366
8 weeks old , 200 g ; n = 5	6397
8 weeks old	6397
200 g ; n = 5	6410
200 g	6410
n = 5	6417
n	6417
5	6421
Plant	6440
et al. -LRB- 2003 -RRB-	6446
et al.	6446
2003	6454
brief	6464
the olfactory nerve layer	6471
the ventral part of the olfactory bulbs	6521
the ventral part	6521
the olfactory bulbs	6541
small pieces	6573
0.25 % trypsin -LRB- Gibco-BRL , USA -RRB-	6605
0.25 % trypsin	6605
Gibco-BRL	6620
USA	6631
50 mg/ml DNase -LRB- Boehringer Mannheim , Germany -RRB-	6640
50 mg/ml DNase	6640
Boehringer Mannheim	6656
Germany	6677
Hank 's	6689
salt solution -LRB- HBSS ; Sigma , USA -RRB- for 60 min	6705
salt solution -LRB- HBSS ; Sigma , USA -RRB-	6705
salt solution	6705
HBSS ; Sigma , USA	6720
HBSS	6720
Sigma , USA	6726
60 min	6742
37 °C	6752
The tissue	6758
a single cell suspension	6795
Cells	6834
low-speed centrifugation	6858
poly-L-lysine	6913
-LRB- PLL ; Sigma -RRB- coated dishes	6928
PLL ; Sigma	6929
PLL	6929
Sigma	6934
The medium	6956
3	6986
4 days and OEG	6988
4 days	6988
OEG	6999
another 4 days	7017
contaminating cells	7065
the low affinity nerve growth factor receptor p75 antibody	7091
Plant	7151
et al. , 2002	7157
et al.	7157
2002	7165
AdV vector infection	7172
transgene expression analysis	7197
optimal transduction	7246
primary OEG cultures	7270
Ruitenberg et al. , 2002a	7322
Ruitenberg	7322
et al.	7333
2002a	7341
OEG	7349
AdV vectors	7372
LacZ or NT-3	7401
a multiplicity of infection -LRB- m.o.i. -RRB- of 100	7418
a multiplicity	7418
infection -LRB- m.o.i. -RRB- of 100	7436
infection -LRB- m.o.i. -RRB-	7436
infection	7436
m.o.i.	7447
100	7458
The calculated dose of recombinant virus	7463
The calculated dose	7463
recombinant virus	7486
the culture medium	7517
the cells	7555
a 37 °C tissue culture incubator	7578
Next day	7611
virus-containing medium	7621
fresh medium	7663
the cells	7680
48 h	7699
initiation of transgene expression	7713
initiation	7713
transgene expression	7727
AdV vector-transduced cells	7749
expression of the LacZ gene	7801
expression	7801
the LacZ gene	7815
X-gal histochemistry	7835
NT-3 mRNA expression using standard non-radioactive in situ	7872
NT-3 mRNA expression	7872
standard non-radioactive in situ	7899
standard non-radioactive	7899
situ	7927
hybridization techniques	7932
Secretion and biological activity of AdV vector-derived NT-3	7958
Secretion and biological activity	7958
AdV vector-derived NT-3	7995
transplantation	8051
Conditioned media from non-modified OEG -	8068
Conditioned media	8068
non-modified OEG	8091
AdV-LacZ - or AdV-NT-3 - -LRB- OEG-LacZ and OEG-NT-3 , respectively -RRB-	8110
AdV-LacZ - or AdV-NT-3 -	8110
AdV-LacZ	8110
AdV-NT-3	8123
OEG-LacZ and OEG-NT-3 , respectively	8134
OEG-LacZ and OEG-NT-3	8134
cell cultures	8182
the presence	8214
AdV vector-derived NT-3	8230
an enzymelinked immunosorbent assay -LRB- ELISA ; Ruitenberg et al. , 2003 -RRB-	8260
an enzymelinked immunosorbent assay	8260
ELISA ; Ruitenberg et al. , 2003	8297
ELISA	8297
Ruitenberg et al. , 2003	8304
Ruitenberg	8304
et al. , 2003	8315
et al.	8315
2003	8323
The EmaxTM immunoassay system -LRB- Promega , USA -RRB-	8330
The EmaxTM immunoassay system	8330
Promega	8361
USA	8370
levels of NT-3 in OEG-conditioned medium	8397
levels	8397
NT-3 in OEG-conditioned medium	8407
NT-3	8407
OEG-conditioned medium	8415
the manufacturer 's instructions	8451
the manufacturer 's	8451
The amount of secreted NT-3	8484
The amount	8484
NT-3	8507
ng of NT-3 derived from a transduced culture per day	8529
ng	8529
NT-3 derived from a transduced culture per day	8535
NT-3	8535
a transduced culture per day	8553
a	8553
culture per day	8566
culture	8566
day	8578
The biological activity of AdV vector-derived NT-3	8583
The biological activity	8583
AdV vector-derived NT-3	8610
assaying neurite outgrowth from dorsal root ganglion -LRB- DRG -RRB- explants	8652
assaying neurite outgrowth	8652
dorsal root ganglion -LRB- DRG -RRB- explants	8684
the methods of Dijkhuizen	8732
the methods	8732
Dijkhuizen	8747
et al. -LRB- 1997 -RRB-	8758
et al.	8758
1997	8766
Embryonic day	8773
15 -LRB- E15 -RRB-	8787
15	8787
E15	8791
DRG explants	8796
48 h in the presence of conditioned medium	8824
48 h	8824
the presence of conditioned medium	8832
the presence	8832
conditioned medium	8848
OEG cultures	8872
AdV-NT - 3 , AdV-LacZ or no virus	8899
AdV-NT	8899
3 , AdV-LacZ or no virus	8907
3	8907
AdV-LacZ	8910
no virus	8922
Neurite outgrowth	8946
the mouse monoclonal antibody 2H3	8984
neurofilament	9026
1 : 1000 ; Developmental Hybridoma Bank , University of Iowa	9041
1 : 1000	9041
Developmental Hybridoma Bank , University of Iowa	9051
Developmental Hybridoma Bank , University	9051
Iowa	9095
IA , USA	9101
IA	9101
USA	9105
Photo images	9111
an IX70 inverted microscope -LRB- Olympus , Melbourne , Australia -RRB-	9141
an IX70 inverted microscope	9141
Olympus	9170
Melbourne	9179
Australia	9190
a Magnafire Digital camera -LRB- Optronics , USA -RRB-	9206
a Magnafire Digital camera	9206
Optronics	9234
USA	9245
In vivo analysis of transgene expression	9251
In vivo analysis	9251
transgene expression	9271
three rats	9309
7 days	9323
post-OEG implantation	9330
sagittal sections	9358
the cervical spinal cord	9384
standard in situ hybridization using digoxygenin -LRB- DIG -RRB-	9432
standard	9432
hybridization	9449
digoxygenin -LRB- DIG -RRB-	9469
digoxygenin	9469
DIG	9482
cRNA antisense probe against NT-3 mRNA -LRB- Ruitenberg et al. , 2003 -RRB-	9496
cRNA antisense probe	9496
NT-3 mRNA -LRB- Ruitenberg et al. , 2003 -RRB-	9525
NT-3 mRNA	9525
Ruitenberg	9536
et al. , 2003	9547
et al.	9547
2003	9555
In vitro characterization	9562
OEG	9602
The purity of OEG cultures used for transplantation	9606
The purity	9606
OEG cultures used for transplantation	9620
OEG cultures	9620
transplantation	9642
immunocytochemistry for antigenic OEG markers	9675
immunocytochemistry	9675
antigenic OEG markers	9699
Glial fibrillary acidic protein -LRB- GFAP -RRB- and S100 protein	9722
Glial fibrillary acidic protein -LRB- GFAP -RRB-	9722
Glial fibrillary acidic protein	9722
GFAP	9755
S100 protein	9765
rabbit anti-cow GFAP	9797
DAKO Corp.	9819
USA	9831
rabbit anti-S100	9839
then	9875
Alexa Fluor1-488	9896
goat anti-rabbit IgG -LRB- Vector Laboratories Inc. , USA -RRB-	9924
goat anti-rabbit IgG	9924
Vector Laboratories Inc. , USA	9946
Vector Laboratories Inc.	9946
USA	9972
Immunoreactivity for low-affinity nerve growth factor receptor p75	9978
Immunoreactivity	9978
low-affinity nerve growth factor receptor p75	9999
Jackson ImmunoResearch Laboratories Inc. , USA	10151
Jackson ImmunoResearch Laboratories Inc.	10151
USA	10193
OEG purity	10199
the ratio of p75-positive cells	10230
the ratio	10230
p75-positive cells	10243
the total cell number -LRB- nuclear stain ; Hoechst 33342 dye -RRB-	10265
the total cell number	10265
nuclear stain ; Hoechst 33342 dye	10288
Hoechst 33342 dye	10303
Hoechst 33342	10303
the culture	10325
transgenic NT-3	10352
a mitogenic effect on adult OEG derived from the olfactory bulb nerve layer	10372
a mitogenic effect	10372
adult OEG derived from the olfactory bulb nerve layer	10394
adult OEG	10394
the olfactory bulb nerve layer	10417
cell proliferation	10449
bromodeoxyuridine -LRB- BrdU ; Roche , Germany -RRB- incorporation	10492
bromodeoxyuridine -LRB- BrdU ; Roche , Germany -RRB-	10492
bromodeoxyuridine	10492
BrdU ; Roche , Germany	10511
BrdU	10511
Roche , Germany	10517
incorporation	10533
OEG	10557
PLL-coated coverslips -LRB- 15 000 cells/12 mm coverslip -RRB- in a 1	10610
PLL-coated coverslips -LRB- 15 000 cells/12 mm coverslip -RRB-	10610
PLL-coated coverslips	10610
15 000 cells/12 mm coverslip	10633
15 000 cells/12	10633
mm coverslip	10649
a 1	10666
1 mixture of Dulbecco 's modified Eagle 's medium -LRB- DMEM ; Sigma -RRB-	10672
1 mixture	10672
Dulbecco 's	10685
Eagle 's medium -LRB- DMEM ; Sigma -RRB-	10705
Eagle 's medium	10705
Eagle 's	10705
DMEM ; Sigma	10721
DMEM	10721
Sigma	10727
Ham 's F-12 nutrient mix -LRB- DF medium -RRB-	10738
Ham 's F-12 nutrient mix	10738
Ham 's	10738
DF medium	10763
10 % fetal bovine serum -LRB- DF-10S -RRB- plus mitogens	10793
10 % fetal bovine serum	10793
DF-10S	10817
mitogens	10830
pituitary extract -LRB- 2 µg/ml ; Sigma -RRB-	10839
pituitary extract	10839
2 µg/ml ; Sigma	10858
2 µg/ml	10858
Sigma	10867
forskolin -LRB- 0.2 µM ; Sigma -RRB-	10878
forskolin	10878
0.2 µM ; Sigma	10889
0.2 µM	10889
Sigma	10897
The following day	10905
the medium	10924
serum-free	10960
CD	10991
medium -LRB- Yan et al. , 2001 -RRB-	10995
medium	10995
Yan	11003
et al. , 2001	11007
et al.	11007
2001	11015
fresh , mitogen-containing DF-10S , and the cells	11024
fresh , mitogen-containing DF-10S	11024
the cells	11062
48 h.	11086
Twelve OEG cultures growing in CD medium	11092
Twelve OEG cultures	11092
CD medium	11123
AdV-LacZ or AdV-NT-3	11159
2 x n = 6 ; m.o.i. 100	11181
2 x	11181
n = 6 ; m.o.i. 100	11185
n = 6	11185
n	11185
6	11189
m.o.i. 100	11192
Additional cultures	11224
triplicate per experimental condition	11258
triplicate	11258
experimental condition	11273
CD medium	11307
DF-10S plus mitogens	11323
DF-10S	11323
mitogens	11335
the addition	11349
increasing amounts	11365
recombinant NT-3	11387
0 , 1 , 10 , 25 , 50 and 100 ng/ml ; Peprotech Inc. , USA	11405
0	11405
1	11408
10	11411
25	11415
50	11419
100 ng/ml ; Peprotech Inc. , USA	11426
100 ng/ml	11426
Peprotech Inc. , USA	11437
Peprotech Inc.	11437
USA	11453
The latter experimental groups	11459
new medium containing freshly thawed NT-3	11510
new medium	11510
NT-3	11547
One day	11553
the first exposure to NT-3	11567
the first exposure	11567
NT-3	11589
all cultures	11595
10 µM BrdU	11625
24 h prior to fixation	11654
24 h	11654
fixation	11668
Uptake of BrdU by dividing cells under the different experimental conditions	11678
Uptake	11678
BrdU by dividing cells under the different experimental conditions	11688
BrdU	11688
cells	11705
the different experimental conditions	11717
immunocytochemistry	11772
a polyclonal sheep anti-BrdU antibody	11798
1 : 1600 ; Fitzgerald , USA	11837
1 : 1600	11837
Fitzgerald , USA	11847
monoclonal S100 antibody	11868
1 : 1000 ; Sigma	11894
1 : 1000	11894
Sigma	11904
OEG	11923
Per experimental condition -LRB- n = 3 -RRB-	11928
Per experimental condition	11928
n	11956
3	11960
photo images	11964
five random fields across each coverslip for cell counts	11991
five random fields	11991
each coverslip for cell counts	12017
each coverslip	12017
cell counts	12036
The fraction of proliferating cells	12049
The fraction	12049
proliferating cells	12065
the ratio of BrdU-positive cells	12105
the ratio	12105
BrdU-positive cells	12118
the total cell number -LRB- Hoechst -RRB-	12141
the total cell number	12141
Hoechst	12164
The whole experiment	12174
A total of just over 72 000 cells	12215
A total	12215
just over 72 000 cells	12226
this experiment	12265
an average number of 824 ± 34 and 3006 ± 75 cells	12287
an average number	12287
824 ± 34 and 3006	12308
75 cells	12328
experimental condition in serum-free and mitogencontaining medium	12349
experimental condition	12349
serum-free and mitogencontaining medium	12375
The biological activity of recombinant NT-3 -LRB- 50 ng/ml -RRB-	12430
The biological activity of recombinant NT-3	12430
The biological activity	12430
recombinant NT-3	12457
50 ng/ml	12475
culture using E15 DRG explants -LRB- prepared as described above -RRB-	12502
culture	12502
E15 DRG explants	12516
Explants -LRB- n = 6 -RRB-	12564
Explants	12564
n	12574
6	12578
NeurobasalTM medium	12595
Gibco	12616
72 h. Explant cultures	12627
nuclear Hoechst	12680
antibodies against pan-neurofilament -LRB- 1 : 500 ; Zymed , USA -RRB-	12704
antibodies	12704
pan-neurofilament -LRB- 1 : 500 ; Zymed , USA -RRB-	12723
pan-neurofilament	12723
1 : 500 ; Zymed , USA	12742
1 : 500	12742
Zymed , USA	12751
S100 protein using standard immunohistochemical techniques	12767
S100 protein	12767
standard immunohistochemical techniques	12786
Spinal cord surgery The methods	12827
Spinal cord surgery	12827
The methods	12847
spinal cord surgery and cell suspension injections	12863
Ruitenberg	12941
et al. , 2002a , b	12952
et al.	12952
2002a	12960
b	12966
the 27 operated rats	12973
the 27	12973
rats	12989
seven	12995
injections of OEG-NT-3	13010
injections	13010
OEG-NT-3	13024
a 1	13036
1 vehicle mix of DF medium , seven	13042
1 vehicle mix	13042
DF medium , seven	13059
DF medium	13059
seven	13070
OEG-LacZ	13095
seven	13105
non-modified OEG	13120
another six	13141
vehicle	13172
Two rats	13187
the surgery	13217
another animal	13233
weight , reacting adversely to the injury ,	13266
weight	13266
the injury	13296
the first postoperative week	13347
24 animals	13382
post-lesion analysis of behaviour	13407
post-lesion analysis	13407
behaviour	13431
An additional three rats	13442
NT-3 mRNA expression in OEG transplants in vivo	13489
NT-3 mRNA expression	13489
OEG transplants in vivo	13513
OEG transplants	13513
vivo	13532
surgery	13554
animals	13563
halothane	13595
1.5 % halothane	13606
1.5 %	13606
halothane	13611
Rhone-Poulenc Chemicals Pty Ltd , Australia	13622
Rhone-Poulenc Chemicals Pty Ltd	13622
Australia	13655
-LRB- v/v -RRB- in 60 % N2O/38 .5 % O2 -RSB-	13666
-LRB- v/v -RRB-	13666
60 % N2O/38 .5 % O2 -RSB-	13675
60 % N2O/38	13675
.5 % O2 -RSB-	13685
A rostral to caudal incision	13694
A rostral	13694
caudal incision	13707
the skin covering the cervical neck region , and the underlying shoulder	13735
the skin	13735
the cervical neck region	13753
the underlying shoulder	13783
muscles	13816
forceps	13845
Laminectomy of the C4 vertebra	13854
Laminectomy	13854
the C4 vertebra	13869
the dura	13903
the spinal cord	13940
A specially designed micro-knife	13957
a 1.5 mm deep medio-lateral incision	14012
1.5 mm	14014
the right half	14056
the spinal cord	14074
the dorsal hemisphere	14115
the CST	14158
A Hamilton syringe -LRB- 5 µl ; Bonaduz , Switzerland -RRB-	14167
A Hamilton syringe	14167
5 µl ; Bonaduz , Switzerland	14187
5 µl	14187
Bonaduz , Switzerland	14193
an attached capillary needle -LRB- tip diameter : 60 µm -RRB-	14220
an attached capillary needle	14220
tip diameter : 60 µm	14250
tip diameter	14250
60 µm	14264
each animal	14288
two injections -LRB- 2x 1 µl ; each containing 100 000 cells -RRB- of OEGNT	14300
two injections -LRB- 2x 1 µl ; each containing 100 000 cells -RRB-	14300
two injections	14300
2x 1 µl ; each containing 100 000 cells	14316
2x 1 µl	14316
each containing 100 000 cells	14325
each	14325
100 000 cells	14341
OEGNT	14359
3 , OEG-LacZ , non-transduced OEG or medium alone	14366
3	14366
OEG-LacZ	14369
non-transduced OEG	14379
medium alone	14401
OEG suspensions for implantation purposes	14415
OEG suspensions	14415
implantation purposes	14435
Ruitenberg	14498
et al. -LRB- 2002a -RRB-	14509
et al.	14509
2002a	14517
The researcher performing spinal surgery and OEG implantation	14525
The researcher	14525
spinal surgery and OEG implantation	14551
spinal surgery	14551
OEG implantation	14570
transplant conditions	14602
Injections	14625
0.5 mm lateral	14646
the dorso-medial sulcus on the right side of the spinal cord	14664
the dorso-medial sulcus	14664
the right side of the spinal cord	14691
the right side	14691
the spinal cord	14709
a depth of 0.8 mm in an attempt	14728
a depth	14728
0.8 mm in an attempt	14739
0.8 mm	14739
an attempt	14749
place theOEGwithin the dorsalCSTprojection area	14763
place theOEGwithin	14763
the dorsalCSTprojection area	14782
The first injection	14812
1 mm proximal to the lesion and the second 1 mm	14841
1 mm	14841
the lesion and the second 1 mm	14857
the lesion	14857
the second 1 mm	14872
the lesion	14898
Shoulder muscles	14910
the skin	14958
Michel surgical clips -LRB- Fine Science Tools , Canada -RRB-	14983
Michel surgical clips	14983
Fine Science Tools , Canada	15006
Fine Science Tools	15006
Canada	15026
the first week	15042
animals	15058
subcutaneous injections	15077
benacillin	15104
150 mg/ml procaine penicillin , 150 mg/ml benzathine penicillin	15116
150 mg/ml procaine penicillin	15116
150 mg/ml benzathine penicillin	15147
20 mg/ml procaine hydrochloride ; Troy Laboratories Pty Ltd , Australia	15180
20 mg/ml procaine hydrochloride	15180
Troy Laboratories Pty Ltd , Australia	15213
Troy Laboratories Pty Ltd	15213
Australia	15240
every second day	15251
daily injections -LRB- 0.3 ml -RRB-	15272
daily injections	15272
0.3 ml	15290
the analgesic buprenorphine hydrochloride	15301
0.3 ml	15344
Reckitt and Colman	15352
UK	15372
Behavioural analysis	15377
BBB open field	15398
scoring Functional performance of impaired fore - to hindlimb coordination	15413
scoring Functional performance of impaired fore	15413
scoring Functional performance	15413
impaired fore	15447
coordination	15474
two independent investigators , blinded to the experimental treatment ,	15507
two independent investigators	15507
the experimental treatment	15549
the Basso -- Beattie -- Bresnahan -LRB- BBB -RRB- locomotor rating scale	15583
Basso -- Beattie -- Bresnahan -LRB- BBB -RRB-	15587
Basso -- Beattie -- Bresnahan	15587
Beattie	15593
BBB	15612
Basso	15641
et al. , 1995	15647
et al.	15647
1995	15655
task and movement analysis	15680
The test apparatus	15707
a clear Perspex test box	15730
an opening	15760
the right side	15774
the anterior wall	15792
an external shelf on which to place food pellets -LRB- see Fig. 2 -RRB-	15814
an external shelf on which to place food pellets	15814
an external shelf	15814
food pellets	15850
Fig. 2	15868
The floor of the box	15877
The floor	15877
the box	15890
a metal grating	15911
a metal	15911
any	15933
food pellets	15945
Dustless precision pellets -LRB- 45 mg ; BioServ , USA -RRB-	15982
Dustless precision pellets	15982
45 mg ; BioServ , USA	16010
45 mg	16010
BioServ , USA	16017
this task	16045
they	16059
the rats to grasp easily	16086
an attractive reward	16124
Food pellets	16146
2.5 cm	16171
the inner edge	16183
the left side	16210
the shelf to encourage the animals to reach with the right forelimb	16227
the animals	16250
the right forelimb	16276
Each pellet	16296
another irrespective of whether it was eaten or dropped	16338
another irrespective	16338
it	16370
A successful reach	16395
the rat	16428
the opening	16452
the food pellet	16473
its right paw	16494
it	16524
its mouth	16530
Successful reaches with the left forelimb	16541
Successful reaches	16541
the left forelimb	16565
An unsuccessful reach	16600
the food pellet	16634
the test box	16669
the food pellet	16686
the shelf outside the test box	16731
the shelf	16731
the test box	16749
this	16763
the pellet	16787
Averaged weekly success ratings	16812
i.e. the number of successful reaches performed in 2 min	16845
i.e. the number	16845
i.e.	16845
the number	16850
successful reaches performed in 2 min	16864
successful reaches	16864
2 min	16896
three independent measurements over a 7 day period	16924
three independent measurements	16924
a 7 day period	16960
the analysis of movements involved in the forelimb reaching task	16980
the analysis	16980
movements involved in the forelimb reaching task	16996
movements	16996
the forelimb reaching task	17018
the forelimb	17018
task	17040
animals	17046
once a week	17066
three different angles	17083
i	17108
a dorsal view	17111
the animal	17141
-LRB- ii -RRB- an anterior view of the whole animal	17153
an anterior view	17158
the whole animal	17178
iii	17201
an anterior close-up of the right forelimb and head	17206
an anterior close-up	17206
the right forelimb and head	17230
Each of the movements involved in forelimb reaching	17259
Each	17259
the movements involved in forelimb reaching	17267
the movements	17267
forelimb reaching	17293
forelimb	17293
the Eshkol -- Wachman movement notation -LRB- Whishaw et al. , 1993 -RRB-	17326
the Eshkol -- Wachman movement notation	17326
Wachman	17337
Whishaw	17364
et al. , 1993	17372
et al.	17372
1993	17380
Anterograde CST	17387
the conclusion of behavioural experiments	17421
the conclusion	17421
behavioural experiments	17439
the 24 rats	17464
halothane -LRB- Rhone-Poulenc Chemicals Pty Ltd , Australia -RRB-	17500
halothane	17500
Rhone-Poulenc Chemicals Pty Ltd	17511
Australia	17544
an incision	17559
the skin covering the skull	17588
the skin	17588
the skull	17606
Two elongated craniotomies	17617
Two	17617
craniotomies	17631
5 mm	17657
either side of the midline from -7.1 mm bregma to + 2.9 mm lambda	17662
either side of the midline from -7.1 mm bregma to	17662
either side	17662
the midline from -7.1 mm bregma	17677
the midline	17677
-7.1 mm bregma	17694
2.9 mm lambda	17714
Anterograde tracer	17729
dextran amine	17761
BDA , 10 % in 2 ml of dH2O ; Molecular Probes , USA	17776
BDA	17776
10 % in 2 ml of dH2O ; Molecular Probes	17781
10 % in 2 ml of dH2O	17781
10 %	17781
2 ml of dH2O	17788
2 ml	17788
dH2O	17796
Molecular Probes	17802
USA	17820
these holes in three oblique injections	17846
these holes	17846
three oblique injections	17861
the sensorimotor cortex in each hemisphere using a Hamilton syringe	17891
the sensorimotor cortex	17891
each hemisphere using a Hamilton syringe	17918
each hemisphere	17918
a Hamilton syringe	17940
BDA conjugated with Texas red -LRB- BDA-R -RRB-	17960
BDA	17960
Texas red	17980
BDA-R	17991
the right cerebral cortex , ipsilateral	18016
the right cerebral cortex	18016
ipsilateral	18043
the spinal cord lesion	18058
BDA conjugated with fluorescein -LRB- BDA-G -RRB-	18090
BDA	18090
fluorescein	18110
BDA-G	18123
the left cortex , contralateral	18148
the left cortex	18148
contralateral	18165
the lesion site	18182
Perfusion and tissue processing	18199
Perfusion	18199
tissue processing	18213
Ten days	18231
cortical tracer injections	18246
animals	18274
0.8 ml	18313
Nembutal	18323
intraperitoneal , pentobarbitone sodium , 60 mg/ml ; Rhone Merieux , Australia	18333
intraperitoneal , pentobarbitone sodium	18333
60 mg/ml ; Rhone Merieux	18373
60 mg/ml	18373
Rhone Merieux	18383
Australia	18398
100 ml of heparinized Dulbecco 's phosphatebuffered saline wash	18442
100 ml	18442
heparinized Dulbecco 's phosphatebuffered saline wash	18452
heparinized Dulbecco 's	18452
100 ml of 4 % paraformaldehyde in Sorenson 's buffer , pH 7.4	18518
100 ml	18518
4 % paraformaldehyde in Sorenson 's buffer , pH 7.4	18528
4 % paraformaldehyde	18528
Sorenson 's buffer , pH 7.4	18551
Sorenson 's buffer	18551
Sorenson 's	18551
pH 7.4	18570
The head and vertebral column	18578
The head	18578
vertebral column	18591
each animal	18628
24 h	18659
The brain and spinal cord	18665
The brain	18665
spinal cord	18679
the skull and vertebra	18711
intact in 0.1 M phosphate buffer -LRB- PB , pH 7.4 -RRB-	18745
intact in 0.1 M phosphate buffer	18745
0.1 M	18755
PB	18779
pH 7.4	18783
The position of the injury in the spinal cord	18792
The position	18792
the injury in the spinal cord	18808
the injury	18808
the spinal cord	18822
the caudal edge of the cerebellum	18856
the caudal edge	18856
the cerebellum	18875
all animals	18906
the same level	18935
A 2 cm segment	18951
the spinal cord	18979
the lesion at the mid-point of this segment	19001
the lesion	19001
the mid-point of this segment	19015
the mid-point	19015
this segment	19032
gelatine	19062
The embedded spinal cords	19072
40 mm thickness	19125
a CO2-freezing microtome -LRB- Polycut , Reichert-Jung , Australia -RRB-	19145
a CO2-freezing microtome	19145
Polycut	19171
Reichert-Jung	19180
Australia	19195
Consecutive series of sections	19207
Consecutive series	19207
sections	19229
24-well plates	19258
0.1 M PB	19284
0.01 % sodium azide -LRB- Sigma -RRB-	19298
0.01 % sodium azide	19298
Sigma	19318
4 °C	19340
immunohistochemistry	19364
Histology Twenty-one of the 24 cortically injected animals	19386
Histology Twenty-one	19386
the 24	19410
animals	19437
BDA tracer	19477
these 21 animals , one -LRB- OEG-NT-3 - transplanted -RRB-	19496
these 21 animals	19496
one -LRB- OEG-NT-3 - transplanted -RRB-	19514
one	19514
OEG-NT-3 - transplanted	19519
OEG-NT-3	19519
rat	19543
an incomplete lesion	19576
the relatively large numbers	19605
BDA-G-labelled fibres	19647
the damaged area	19691
one area	19739
a straight parallel bundle reminiscent of the intact anatomical projection	19765
a straight parallel bundle reminiscent	19765
the intact anatomical projection	19807
axon terminations	19854
the distal grey matter of the spinal cord segment	19893
the distal grey matter	19893
the spinal cord segment	19919
this animal	19944
further histological analysis	19974
sectioning	20011
the first complete spinal cord section	20023
the number 1	20075
this	20089
the lateral right-most part of the spinal cord	20100
the lateral right-most part	20100
the spinal cord	20131
Approximately 50 sections	20148
spinal cord	20193
Every eighth section on the lesioned side	20206
Every eighth section	20206
the lesioned side	20230
GFAP	20270
reactive astrocytes	20288
the lesion area	20311
Sections	20328
these	20349
p75	20378
a surface receptor	20383
the vast majority of OEG	20436
the vast majority	20436
OEG	20457
their transplantation	20467
injured spinal cord -LRB- Ruitenberg et al. , 2002a -RRB-	20494
injured spinal cord	20494
Ruitenberg	20515
et al. , 2002a	20526
et al.	20526
2002a	20534
Fluorophore-conjugated secondary antibodies	20542
labelled cells	20609
The immunohistochemical procedures	20625
GFAP and p75 staining on lesioned spinal cord tissue	20664
GFAP and p75 staining	20664
lesioned spinal cord tissue	20689
Ruitenberg	20744
et al. , 2002a , 2003	20755
et al.	20755
2002a	20763
2003	20770
Quantification of BDA-labelled CST axons	20777
Quantification	20777
BDA-labelled CST axons	20795
All sagittal sections	20818
BDA-G-labelled axons	20855
low magnification -LRB- x4 objective -RRB-	20904
low magnification	20904
x4 objective	20923
a BioRad MRC-1000	20943
confocal laser-scanning microscope attached to a Nikon Optiphot-2 microscope	20961
confocal laser-scanning microscope	20961
a Nikon Optiphot-2 microscope	21008
Centre for Microscopy and Microanalysis , UWA	21039
Centre	21039
Microscopy and Microanalysis	21050
UWA	21080
Quantitative comparisons of BDA-G-labelled axons	21086
Quantitative comparisons	21086
BDA-G-labelled axons	21114
the level of fluorescence	21149
the level	21149
fluorescence	21162
each section	21178
a computerized image analysis program	21198
ImageSpace , Molecular Dynamics	21237
ImageSpace	21237
Molecular Dynamics	21249
background and non-specific staining in each image	21270
background and non-specific staining	21270
each image	21310
the intensity thresholds	21346
The length and density of BDA-G-labelled axons across the lesion	21372
The length and density	21372
BDA-G-labelled axons across the lesion	21398
BDA-G-labelled axons	21398
the lesion	21426
measurements	21463
four distances -LRB- Fig. 5A and B -RRB-	21479
four distances	21479
Fig. 5A and B	21495
Fig. 5A	21495
B	21507
1 mm proximal to the middle of the lesion site -LRB- -1 mm -RRB-	21511
1 mm proximal to the middle of the lesion site	21511
1 mm	21511
the middle of the lesion site	21528
the middle	21528
the lesion site	21542
-1 mm	21559
the middle of the lesion -LRB- 0 mm -RRB-	21567
the middle	21567
the lesion -LRB- 0 mm -RRB-	21581
the lesion	21581
0 mm	21593
0.5 mm	21600
the middle of the lesion -LRB- + 0.5 mm -RRB-	21617
the middle	21617
the lesion -LRB- + 0.5 mm -RRB-	21631
the lesion	21631
+	21644
0.5 mm	21646
0.5	21646
mm	21650
1 mm	21658
the middle -LRB- + 1.0 mm -RRB-	21673
the middle	21673
+	21685
1.0 mm	21687
1.0	21687
mm	21691
each distance	21699
a measure of fluorescence	21714
a measure	21714
fluorescence	21727
number of pixels within the altered thresholds x average pixel intensity	21754
number	21754
pixels within the altered thresholds x average pixel intensity	21764
pixels	21764
the altered thresholds x average pixel intensity	21778
the altered thresholds	21778
average pixel intensity	21803
The initial adjustment of intensity thresholds	21829
The initial adjustment	21829
intensity thresholds	21855
all background signal	21903
each image	21930
this	21957
measurements from three areas of ventral white matter	21963
measurements	21963
three areas of ventral white matter	21981
three areas	21981
ventral white matter	21996
representative of background staining	22018
representative	22018
background staining	22036
a value	22079
background fluorescence	22091
signal fluorescence	22147
the four distances across the lesion site	22170
the four distances	22170
the lesion site	22196
addition to the quantitative analysis in sagittal sections	22216
addition	22216
the quantitative analysis in sagittal sections	22228
the quantitative analysis	22228
sagittal sections	22257
additional analysis of signal fluorescence in the lesioned CST projection	22276
additional analysis	22276
signal fluorescence in the lesioned CST projection	22299
signal fluorescence	22299
the lesioned CST projection	22322
transverse sections -LRB- 40 mm -RRB-	22367
transverse sections	22367
40 mm	22388
1 cm proximal	22403
1 cm	22403
1 cm distal from the lesion epicentre	22424
1 cm	22424
the lesion epicentre	22441
Digital images	22463
a free form profile measurement tool	22512
the labelled and non-labelled areas	22562
The intensity of fluorescence	22599
The intensity	22599
fluorescence	22616
1 cm proximal and 1 cm distal	22650
1 cm	22650
1 cm	22668
a percentage label	22699
Background fluorescence	22719
the final value	22763
Assessment	22801
spinal tissue sparing Every fourth sagittal section from the spinal cord	22815
spinal tissue	22815
Every fourth sagittal section	22837
the spinal cord	22872
the volume of spared tissue -LRB- Plant et al. , 2003 -RRB-	22910
the volume	22910
spared tissue -LRB- Plant et al. , 2003 -RRB-	22924
spared tissue	22924
Plant	22939
et al. , 2003	22945
et al.	22945
2003	22953
The analysis	22960
five rats	22990
each of the mediuminjected or OEG - , OEG-LacZ - and OEG-NT-3-implanted groups	23005
each of the mediuminjected or OEG - , OEG-LacZ	23005
each of the mediuminjected or OEG	23005
each	23005
the mediuminjected or	23013
the mediuminjected	23013
OEG-LacZ	23041
OEG-NT-3-implanted groups	23055
each section	23085
the pixel number	23099
the damaged area	23119
the total number of pixels in a 2.5 mm long spinal cord segment	23140
the total number	23140
pixels in a 2.5 mm long spinal cord segment	23160
pixels	23160
a 2.5 mm	23170
spinal cord segment	23184
the lesion epicentre in the middle	23210
the lesion epicentre	23210
the middle	23234
The border of the damaged area	23260
The border	23260
the damaged area	23274
an obvious discontinuity in the density of small cells , i.e.	23306
an obvious discontinuity	23306
the density of small cells	23334
the density	23334
small cells	23349
transplanted cells and inflammatory cells	23367
transplanted cells	23367
inflammatory cells	23390
the absence of healthy looking spinal neurons	23414
the absence	23414
healthy looking spinal neurons	23429
This area	23461
the grafted cells and usually some small cysts	23481
the grafted cells	23481
usually some small cysts	23503
Measurements from each section	23529
Measurements	23529
each section	23547
rat	23576
the total number of sections	23598
the total number	23598
sections	23618
spinal tissue	23635
the difference	23670
the number	23693
pixels	23707
the area	23717
damaged tissue -LRB- cyst area and degenerate area -RRB-	23729
damaged tissue	23729
cyst area and degenerate area	23745
cyst area	23745
degenerate area	23759
the number of pixels in the whole segment	23780
the number	23780
pixels in the whole segment	23794
pixels	23794
the whole segment	23804
Similar methods	23823
graft size	23864
p75-stained sections	23882
there	23907
a concordance	23916
p75 staining and OEG viability	23938
up to 4 months after transplantation -LRB- Ruitenberg et al. , 2002a -RRB-	23973
up to 4 months	23973
transplantation -LRB- Ruitenberg et al. , 2002a -RRB-	23994
transplantation	23994
Ruitenberg	24011
et al. , 2002a	24022
et al.	24022
2002a	24030
The relative amount of degenerate tissue	24038
The relative amount	24038
degenerate tissue	24061
the number of pixels in the p75-positive area	24114
the number	24114
pixels in the p75-positive area	24128
pixels	24128
the p75-positive area	24138
the total pixel number of the damaged area	24165
the total pixel number	24165
the damaged area	24191
Statistical analysis All statistical analysis	24209
Statistical analysis	24209
All statistical analysis	24230
standard statistics computer software -LRB- SPSS for Windows , Release 10 -RRB-	24272
standard statistics computer software	24272
SPSS for Windows , Release 10	24311
SPSS	24311
Windows	24320
Release 10	24329
Data sets	24342
significance	24370
one-way and repeated measures ANOVA -LRB- analysis of variance -RRB-	24389
one-way and repeated measures	24389
ANOVA -LRB- analysis of variance -RRB-	24419
ANOVA	24419
analysis of variance	24426
analysis	24426
variance	24438
simple contrast tests	24451
All data	24474
means = SEM	24503
Fig. 5C , which shows means 6 SD to better visualize intra-group variation	24525
Fig. 5C	24525
6 SD	24552
better visualize intra-group variation	24560
better	24560
intra-group variation	24577
Results	24601
1	24614
In vitro and in vivo analysis of AdV vector-mediated transgene expression	24616
In vitro and in vivo analysis	24616
vivo	24632
AdV vector-mediated transgene expression	24649
-LRB- A -RRB- X-Gal cytochemistry of primary OEG	24691
-LRB- A -RRB- X-Gal cytochemistry	24691
A	24692
primary OEG	24718
72 h after transduction with AdV-LacZ vector	24731
72 h	24731
transduction with AdV-LacZ vector	24742
transduction	24742
AdV-LacZ vector	24760
Virtually all cultured cells	24777
Virtually all	24777
cells	24800
the LacZ gene product	24816
-LRB- B -RRB-	24839
a cRNA probe	24849
NT-3 mRNA , cells transduced with AdV-NT-3 vector	24875
NT-3 mRNA	24875
cells transduced with AdV-NT-3 vector	24886
cells	24886
AdV-NT-3 vector	24908
high levels of this neurotrophin	24934
high levels	24934
this neurotrophin	24949
72 h	24973
-LRB- C -RRB- Conditioned medium from AdV-NT-3 vector-transduced OEG cells	24988
-LRB- C -RRB- Conditioned medium	24988
C	24989
AdV-NT-3 vector-transduced OEG cells	25016
E15 dorsal root ganglion -LRB- DRG -RRB-	25066
E15 dorsal root ganglion	25066
DRG	25092
cultures and neurite outgrowth	25097
cultures	25097
neurite outgrowth	25110
48 h. AdV	25157
vector-derived NT-3 in OEG conditioned medium	25167
vector-derived NT-3	25167
OEG conditioned medium	25190
the induction of robust neurite growth	25257
the induction	25257
robust neurite growth	25274
DRG explants	25310
-LRB- D -RRB- Higher magnification of the outlined area	25324
Higher magnification	25328
the outlined area	25352
C showing neurite extensions with growth cone-like structures	25373
C	25373
neurite extensions	25383
growth cone-like structures	25407
-LRB- E -RRB- Conditioned medium taken from control	25436
-LRB- E -RRB- Conditioned medium	25436
E	25437
control	25470
OEG-LacZ	25479
cultures	25489
very little outgrowth	25506
DRG explants	25533
-LRB- F -RRB-	25547
In vivo confirmation of AdV	25551
In vivo confirmation	25551
AdV	25575
vector-mediated NT-3 expression at 7 days after injection of AdV-NT-3	25579
vector-mediated NT-3 expression	25579
7 days after injection of AdV-NT-3	25614
7 days	25614
injection of AdV-NT-3	25627
injection	25627
AdV-NT-3	25640
vector-transduced OEG suspensions into the lesioned spinal cord	25649
vector-transduced OEG suspensions	25649
the lesioned spinal cord	25688
Scale bars : A , B = 83 µm ; C , E = 1 mm ; D = 275 µm ; F = 170 µm .	25714
Scale bars	25714
A , B = 83 µm	25726
A	25726
B = 83 µm	25729
B	25729
= 83 µm	25731
83	25733
C , E = 1 mm	25740
C	25740
E = 1 mm	25743
E	25743
= 1 mm	25745
1	25747
D = 275 µm	25753
D	25753
= 275 µm	25755
275	25757
F = 170 µm	25765
F	25765
= 170 µm	25767
170	25769
Fig. 2 Behavioural assessment of forepaw function in experimental animals .	25778
Fig.	25778
2 Behavioural assessment of forepaw function in experimental animals	25783
2 Behavioural assessment	25783
forepaw function in experimental animals	25811
forepaw function	25811
experimental animals	25831
-LRB- A -RRB- Pre-surgery skilled forepaw movements	25853
-LRB- A -RRB-	25853
Pre-surgery skilled forepaw movements	25857
experimental rats	25910
All animals	25929
the opening with their right forepaw	25983
the opening	25983
their right forepaw	26000
they	26021
the food pellet	26034
it	26081
their mouth	26087
3 weeks after the surgery	26103
3 weeks	26103
the surgery	26117
pellet retrieval	26130
all experimental animals , i.e. the lesioned forepaw was paralysed	26172
all experimental animals	26172
i.e. the lesioned forepaw was paralysed	26198
i.e.	26198
the lesioned forepaw	26203
the rats	26242
the skilled reaches that are required to grab the food pellet reward	26278
the skilled reaches	26278
the food pellet reward	26324
12 weeks after surgery	26351
12 weeks	26351
surgery	26366
success ratings in pellet retrieval	26375
success ratings	26375
pellet retrieval	26394
all experimental groups	26444
further analysis	26473
there	26502
no concurrent improvement in Eshkol	26512
no concurrent improvement	26512
Eshkol	26541
Wachman movement notation for the impaired forepaw	26548
Wachman movement notation	26548
the impaired forepaw	26578
The animals	26600
partial forepaw paralysis	26627
the head and shoulders	26664
an anti-clockwise motion almost 90 ° , such	26690
an anti-clockwise motion	26690
almost 90 °	26715
the lesioned forelimb	26737
the	26737
forelimb	26750
the air	26773
This forepaw	26782
the food pellet	26818
the limb	26838
it	26870
the animals mouth as illustrated	26878
the animals mouth	26878
illustrated	26899
Components such as grasp , supination and release	26912
Components	26912
grasp , supination and release	26931
-LRB- B -RRB- Weekly averages of success ratings , i.e.	26984
-LRB- B -RRB-	26984
Weekly averages of success ratings , i.e.	26988
Weekly averages	26988
success ratings	27007
the number of pellets	27029
the number	27029
pellets	27043
2 min time interval	27065
each of the four groups before lesioning and during the testing period	27090
each	27090
the four groups before lesioning and during the testing period	27098
the four groups	27098
the testing period	27142
the -LRB- spontaneous -RRB- improvement	27167
spontaneous	27172
that	27197
time in all groups	27220
time	27220
all groups	27228
-LRB- C -RRB- Weekly averages of Eshkol	27240
Weekly averages	27244
Eshkol	27263
Wachman movement notation	27270
Wachman	27270
movement notation	27278
rating of skilled forelimb use	27302
rating	27302
skilled forelimb use	27312
each of the four groups	27338
each	27338
the four groups	27346
-LRB- D -RRB-	27372
` Success versus movement ' analysis	27376
movement	27392
an individual animal	27414
that animal 11	27518
a simultaneous improvement	27546
pellet retrieval success and forelimb movement rating from week 7	27576
pellet retrieval success and forelimb movement rating	27576
week 7	27635
9	27645
no such parallel recovery	27656
animal 18	27698
Fig. 3 Graphic	27710
representation and confocal photomicrographs of dual-coloured anterograde	27725
representation and confocal photomicrographs	27725
dual-coloured anterograde	27773
CST in normal and spinal cord-injured animals	27799
CST	27799
normal and spinal cord-injured animals	27806
-LRB- A -RRB- Schematic diagram	27846
A	27847
the tracer injection sites and subsequent labelling	27871
the tracer injection	27871
the different sensorimotor	27926
cortical hemispheres and CST projections	27953
cortical hemispheres	27953
CST projections	27978
-LRB- B -RRB- Representative horizontal spinal cord section showing the two	27995
-LRB- B -RRB- Representative horizontal spinal cord section	27995
-LRB- B -RRB-	27995
Representative horizontal spinal cord section	27999
the two	28053
CST projections	28083
an uninjured control animal	28102
-LRB- C -RRB- Transverse section through the cervical -LRB- C4 -RRB- spinal cord	28131
-LRB- C -RRB- Transverse section	28131
C	28132
the cervical -LRB- C4 -RRB- spinal cord	28162
C4	28176
the dorsal column region	28201
CST projections	28239
the distinct labelling of axons within both CST projections	28261
the distinct labelling	28261
axons within both CST projections	28287
axons	28287
both CST projections	28300
Only occasional BDA-G-positive fibres	28322
the BDA-R-labelled CST	28373
vice	28401
Representative confocal photomicrograph	28417
an OEG-LacZ transplanted rat , 12 weeks post-surgery , showing successfully	28460
an OEG-LacZ transplanted rat , 12 weeks post-surgery ,	28460
an OEG-LacZ transplanted rat	28460
12 weeks post-surgery	28490
BDA-G-labelled	28544
CST axons	28560
the BDA-R-labelled CST	28576
CST axons	28626
enlarged , bulbous ends	28650
large fibre masses	28678
the rostral edge of the lesion site	28721
the rostral edge	28721
the lesion site	28741
Virtually no regrowth of lesioned CST axons	28758
Virtually no regrowth	28758
lesioned CST axons	28783
animals receiving control -LRB- OEG and OEG-LacZ -RRB- implants	28817
animals	28817
control -LRB- OEG and OEG-LacZ -RRB-	28835
control	28835
OEG and OEG-LacZ	28844
OEG	28844
OEG-LacZ	28852
implants	28862
-LRB- E -RRB- Consecutive section	28872
-LRB- E -RRB-	28872
Consecutive section	28876
GFAP-positive hyperactive astrocytes	28904
the lesion and implantation site	28953
cc = central canal ; gm = grey matter ; wm = white matter .	28987
cc = central canal	28987
cc	28987
= central canal	28990
gm = grey matter	29007
gm	29007
= grey matter	29010
wm = white matter	29025
wm	29025
= white matter	29028
Scale bars : B = 374 µm ; C = 178 µm ; D , E = 227 µm .	29044
Scale bars	29044
B = 374 µm	29056
B	29056
= 374 µm	29058
C = 178 µm	29068
C	29068
= 178 µm	29070
178	29072
D , E = 227 µm	29080
D	29080
E = 227 µm	29083
E	29083
= 227 µm	29085
Fig. 4 Transplant purity and distal CST axons in OEG-NT-3-transplanted rats .	29096
Fig.	29096
4 Transplant purity and distal CST axons	29101
4 Transplant purity	29101
distal CST axons	29125
OEG-NT-3-transplanted rats	29145
-LRB- A -RRB-	29173
immunopanning	29183
primary OEG cultures for transplantation purposes	29198
primary OEG cultures	29198
transplantation purposes	29223
p75-positive -LRB- red -RRB- cells and between 95 and 98 % pure	29265
p75-positive -LRB- red -RRB- cells	29265
between 95 and 98 % pure	29294
the ratio of p75-positive cells and the total number of Hoechst	29337
the ratio of p75-positive cells	29337
the ratio	29337
p75-positive cells	29350
the total number of Hoechst	29373
the total number	29373
Hoechst	29393
dye-positive -LRB- blue -RRB- nuclei	29401
OEG	29438
GFAP -LRB- green -RRB-	29471
GFAP	29471
-LRB- B -RRB- Representative image	29485
B	29486
intense p75 immunoreactivity -LRB- asterisk -RRB-	29513
intense p75 immunoreactivity	29513
asterisk	29543
the lesion and implantation site	29556
12 weeks after surgery	29590
12 weeks	29590
surgery	29605
OEG-transplanted animals only	29629
OEG-transplanted animals	29629
Low-power micrograph	29664
a typical OEG-NT-3-transplanted rat at 12 weeks after surgery	29688
a typical OEG-NT-3-transplanted rat	29688
12 weeks after surgery	29727
12 weeks	29727
surgery	29742
Distal BDA-G-labelled CST axons -LRB- arrows -RRB-	29751
Distal BDA-G-labelled CST axons	29751
arrows	29784
the proximal mass -LRB- white line -RRB-	29806
the proximal mass	29806
white line	29825
the lesion area	29848
the more ventral portions	29872
1 cm distally	29932
1 cm	29932
Higher magnification	29951
the lesion and implantation area , -LRB- outlined by the dashed line -RRB-	29975
the lesion and implantation area ,	29975
the lesion	29975
implantation area	29990
the dashed line	30022
a significant number of BDA-G-labelled CST axons	30084
a significant number	30084
BDA-G-labelled CST axons	30108
arrows	30134
the ventral portions of the damaged area	30151
the ventral portions	30151
the damaged area	30175
the opposing part of the spinal cord	30211
the opposing part	30211
the spinal cord	30232
-LRB- E -RRB- Transverse spinal cord section	30249
-LRB- E -RRB-	30249
Transverse spinal cord section	30253
1 cm distal to the C4 lesion site	30285
1 cm	30285
the C4 lesion site	30300
an OEG-LacZ-transplanted rat	30331
12 weeks	30363
surgery	30378
the presence	30392
BDA-R-positive axons in the intact CST projection -LRB- left -RRB-	30408
BDA-R-positive axons	30408
the intact CST projection -LRB- left -RRB-	30432
the intact CST projection	30432
left	30459
BDA-G-labelled axons	30473
the degenerated projection area	30508
the lesioned side of the spinal cord -LRB- dashed line -RRB-	30543
the lesioned side	30543
the spinal cord	30564
line	30588
the completeness of the injury	30609
the completeness	30609
the injury	30629
-LRB- F -RRB- Scattered BDA-G-labelled fibres	30641
-LRB- F -RRB-	30641
BDA-G-labelled fibres	30655
1 cm distal to the injury site in OEG-NT-3-transplanted animals	30690
1 cm	30690
the injury site in OEG-NT-3-transplanted animals	30705
the injury site	30705
OEG-NT-3-transplanted animals	30724
CST = corticospinal tract ; gm = grey matter ; wm = white matter .	30760
CST = corticospinal tract	30760
CST	30760
= corticospinal tract	30764
gm = grey matter	30787
gm	30787
= grey matter	30790
wm = white matter	30805
wm	30805
= white matter	30808
Scale bars : A = 41 µm ; B = 91 µm ; C = 870 µm ; D = 279 µm ; E , F = 71 µm .	30824
Scale bars	30824
A = 41 µm	30836
A	30836
= 41 µm	30838
41	30840
B = 91 µm	30847
B	30847
= 91 µm	30849
91	30851
C = 870 µm	30858
C	30858
= 870 µm	30860
870	30862
D = 279 µm	30870
D	30870
= 279 µm	30872
279	30874
E , F = 71 µm	30882
E	30882
F = 71 µm	30885
F	30885
= 71 µm	30887
71	30889
Fig.	30897
5 Quantitative analysis	30902
distal CST axons at 12 weeks after injury and OEG implantation	30929
distal CST axons	30929
12 weeks after injury and OEG implantation	30949
12 weeks	30949
injury and OEG implantation	30964
-LRB- A -RRB- Typical example	30993
A	30994
a confocal microscope image of an OEG-implanted animal	31016
a confocal microscope image	31016
an OEG-implanted animal	31047
a sagittal section	31080
the spinal cord with the lesion epicentre in the middle	31107
the spinal cord	31107
the lesion epicentre in the middle	31128
the lesion epicentre	31128
the middle	31152
-LRB- B -RRB-	31164
image	31178
A	31187
the computer	31206
fibre fluorescence	31231
image analysis software	31256
The position of the vertical bars	31281
The position	31281
the vertical bars	31297
the regions of analysis	31325
the regions	31325
analysis	31340
-LRB- C -RRB- Measurements of BDA-G-labelled axons at the lesion	31350
-LRB- C -RRB- Measurements	31350
C	31351
BDA-G-labelled axons at the lesion	31370
BDA-G-labelled axons	31370
the lesion	31394
site	31405
sagittal spinal cord sections from all experimental groups	31428
sagittal spinal cord sections	31428
all experimental groups	31463
pixels of fluorescence	31504
pixels	31504
fluorescence	31514
mean 6 SD	31528
mean	31528
6 SD	31533
There	31540
a trend	31550
increased numbers	31566
axons	31587
the more distal parts	31596
the lesion and implantation site in OEG-NT-3-implanted animals	31621
the lesion and implantation site	31621
OEG-NT-3-implanted animals	31657
Quantification	31689
BDA-G-traced CST axons	31707
transverse spinal cord sections , 1 cm distal to the injury site	31733
transverse spinal cord sections	31733
1 cm distal to the injury site	31766
1 cm	31766
the injury site	31781
The obtained measurements	31798
the percentage of total fluorescence	31841
the percentage	31841
total fluorescence	31859
1 cm proximal to the injury site	31881
1 cm	31881
the injury site	31898
variability	31932
efficiency of CST	31947
efficiency	31947
CST	31961
relative percentage of fluorescence intensity ± SEM	31974
relative percentage of fluorescence intensity	31974
relative percentage	31974
fluorescence intensity	31997
± SEM	32020
Significantly more distal BDA-G-labelled fibres	32028
OEG-NT-3-implanted rats	32093
all other experimental animal groups -LRB- P ≤ 0.0005 -RRB-	32131
all other experimental animal groups	32131
P ≤ 0.0005	32169
P	32169
≤ 0.0005	32171
Fig. 6 OEG implants	32183
Fig.	32183
6 OEG implants	32188
the spinal cord lesion size	32210
tissue	32251
-LRB- A -RRB- Statistical analysis	32259
-LRB- A -RRB-	32259
Statistical analysis	32263
the mean percentage of spared spinal tissue	32296
the mean percentage	32296
spared spinal tissue	32319
all OEG-transplanted animal groups	32369
vehicle-injected controls -LRB- P ≤ 0.006 -RRB-	32418
vehicle-injected controls	32418
P ≤ 0.006	32445
P	32445
≤ 0.006	32447
-LRB- B -RRB- No significant changes in total cyst number	32457
-LRB- B -RRB-	32457
No significant changes in total cyst number	32461
No significant changes	32461
total cyst number	32487
cystic -LRB- pixel -RRB- area	32509
pixel	32517
the different experimental groups	32547
-LRB- C -RRB-	32582
The area of degenerate tissue	32586
The area	32586
degenerate tissue	32598
all OEG-implanted animals	32645
the OEG-NT-3-transplanted animal group -LRB- P < 0.004 -RRB- -LRB- D -RRB-	32699
the OEG-NT-3-transplanted animal group -LRB- P < 0.004 -RRB-	32699
the OEG-NT-3-transplanted animal group	32699
P < 0.004	32739
P	32739
< 0.004	32741
<	32741
0.004	32743
D	32751
The p75-positive -LRB- pixel -RRB- area in the grafted region	32755
The p75-positive -LRB- pixel -RRB- area	32755
pixel	32773
the grafted region	32788
OEGand OEG-LacZ-transplanted rats	32835
implantation of AdV-NT-3-transduced OEG -LRB- P < 0.004 -RRB-	32906
implantation	32906
AdV-NT-3-transduced OEG -LRB- P < 0.004 -RRB-	32922
AdV-NT-3-transduced OEG	32922
P < 0.004	32947
P	32947
< 0.004	32949
<	32949
0.004	32951
A single asterisk	32959
statistical significance	32987
vehicle-injected lesioned control animals	33017
double asterisks	33068
significance of OEG-NT-3-transplanted rats	33093
significance	33093
OEG-NT-3-transplanted rats	33109
all other experimental groups	33150
Fig. 7	33182
In vitro analysis of mitogenic effects of NT-3	33189
In vitro analysis	33189
mitogenic effects of NT-3	33210
mitogenic effects	33210
NT-3	33231
adult OEG	33248
A and B	33260
A	33260
B	33266
Proliferation of	33269
Proliferation	33269
adult OEG	33295
the rat olfactory bulb nerve layer , in DF-10S medium	33320
the rat	33320
bulb nerve layer , in DF-10S medium	33338
bulb nerve layer	33338
the absence -LRB- A -RRB- and presence of NT-3 -LRB- B ; 50 ng/ml -RRB-	33376
the absence -LRB- A -RRB-	33376
the absence	33376
A	33389
presence of NT-3 -LRB- B ; 50 ng/ml -RRB-	33396
presence	33396
NT-3 -LRB- B ; 50 ng/ml -RRB-	33408
NT-3	33408
B ; 50 ng/ml	33414
B	33414
50 ng/ml	33417
Cultures	33428
S100 -LRB- green -RRB- , BrdU -LRB- red -RRB- and Hoechst dye -LRB- blue -RRB-	33461
S100 -LRB- green -RRB-	33461
S100	33461
BrdU -LRB- red -RRB- and Hoechst dye -LRB- blue -RRB-	33475
BrdU -LRB- red -RRB-	33475
BrdU	33475
red	33481
Hoechst dye -LRB- blue -RRB-	33490
Hoechst	33490
proliferating cells	33513
the nuclear co-localization of BrdU signal and Hoechst	33534
the nuclear co-localization	33534
BrdU signal and Hoechst	33565
BrdU signal	33565
Hoechst	33581
results in a purple nuclear	33593
results	33593
a purple nuclear	33604
-LRB- C -RRB- Quantitative analysis of OEG proliferation	33628
-LRB- C -RRB- Quantitative analysis	33628
C	33629
OEG proliferation	33657
cells	33681
CD - or DF-10S medium , containing various amounts of NT-3 ,	33713
CD - or DF-10S medium	33713
various amounts of NT-3	33746
various amounts	33746
NT-3	33765
AdV-NT-3	33790
the percentage of proliferating cells	33813
the percentage	33813
proliferating cells	33831
medium	33869
no serum , pituitary extract and forskolin	33888
no serum	33888
pituitary extract	33898
forskolin	33920
No evidence	33931
NT-3	33958
cells	33995
recombinant protein	34013
the culture medium	34036
a mitogenic effect on OEG -LRB- P > 0.05 -RRB-	34060
a mitogenic effect	34060
OEG -LRB- P > 0.05 -RRB-	34082
OEG	34082
P > 0.05	34087
P	34087
> 0.05	34089
>	34089
0.05	34091
D and E -RRB- Confirmation	34099
the biological activity of recombinant NT-3	34124
the biological activity	34124
recombinant NT-3	34151
E15 DRG explants	34169
pan-neurofilament -LRB- green -RRB- , S100 protein -LRB- red -RRB-	34213
pan-neurofilament -LRB- green -RRB-	34213
pan-neurofilament	34213
S100 protein -LRB- red -RRB-	34240
S100 protein	34240
red	34254
Hoechst	34263
blue nuclear	34276
the absence of NT-3	34304
the absence	34304
NT-3	34319
virtually no neurite extension from DRG explants	34325
virtually no neurite extension	34325
DRG explants	34361
addition of NT-3 -LRB- 50 ng/ml -RRB- to the culture medium	34405
addition	34405
NT-3 -LRB- 50 ng/ml -RRB- to the culture medium	34417
NT-3 -LRB- 50 ng/ml -RRB-	34417
NT-3	34417
50 ng/ml	34423
the culture medium	34436
robust , radial fibre outgrowth	34463
the explant	34499
the increased dispersal of Schwann cells in the presence of NT-3	34517
the increased dispersal	34517
Schwann cells in the presence of NT-3	34544
Schwann cells	34544
the presence of NT-3	34561
the presence	34561
NT-3	34577
Scale bars : A , B = 50 µm ; D , E = 100 µm .	34583
Scale bars	34583
A , B = 50 µm	34595
A	34595
B = 50 µm	34598
B	34598
= 50 µm	34600
50	34602
D , E = 100 µm	34609
D	34609
E = 100 µm	34612
E	34612
= 100 µm	34614
100	34616
Analysis of transgene expression	34625
Analysis	34625
transgene expression	34637
Primary p75-purified OEG cultures	34658
first generation E1-deleted AdV vectors	34725
LacZ or NT-3	34774
m.o.i. 100 ; Fig. 1A and B	34788
m.o.i. 100	34788
Fig. 1A and B	34800
High levels of transgene expression	34816
High levels	34816
transgene expression	34831
> 95 % of the cells	34872
> 95 %	34872
>	34872
the cells	34880
3 days	34904
infection	34917
Transduced cells	34928
similar morphology	34955
OEG cultures	34985
cytotoxicity	34999
control cultures	35032
no expression of either LacZ or NT-3 -LRB- not shown -RRB-	35056
no expression	35056
either LacZ or NT-3	35073
LacZ	35080
NT-3	35088
Conditioned medium from OEG cultures	35106
Conditioned medium	35106
OEG cultures	35130
the presence of NT-3	35160
the presence	35160
NT-3	35176
standard ELISA	35187
4 days	35203
AdV vector transduction	35216
AdV-NT-3 vector-transduced cultures	35241
net NT-3 levels of 40 ±	35286
net NT-3 levels	35286
40 ±	35305
7.4 ng/10	35310
^ 5 cells/24	35319
NT-3 protein	35334
non-transduced and OEGLacZ cultures	35372
Biological activity of AdV vector-derived NT-3	35409
Biological activity	35409
AdV vector-derived NT-3	35432
neurite outgrowth	35483
embryonic DRG explants in the presence of conditioned medium	35506
embryonic DRG explants	35506
the presence of conditioned medium	35532
the presence	35532
conditioned medium	35548
OEG cultures	35572
2 days	35592
robust neurite outgrowth	35600
DRG explants	35648
supernatant	35670
OEGNT - 3 cultures -LRB- Fig. 1C and D -RRB-	35687
OEGNT	35687
3 cultures	35694
Fig. 1C and D	35706
Fig. 1C	35706
D	35718
Virtually no neuritic growth	35722
DRG explants	35769
conditioned medium	35801
either non-transduced OEG or OEGLacZ cultures	35825
non-transduced OEG	35832
OEGLacZ cultures	35854
Fig. 1E	35872
In vivo analysis of transgene expression	35882
In vivo analysis	35882
transgene expression	35902
endogenous levels	35947
there	35966
robust NT-3 mRNA expression	35976
the damaged area at 7 days post-implantation -LRB- Fig. 1F -RRB-	36007
the damaged area	36007
7 days post-implantation -LRB- Fig. 1F -RRB-	36027
7 days post-implantation	36027
Fig. 1F	36053
Numerous labelled cells of bipolar OEG morphology	36063
Numerous	36063
cells of bipolar OEG morphology	36081
cells	36081
bipolar OEG morphology	36090
the transplantation area	36130
No such staining	36156
animals that received injections with OEG-LacZ or ` medium only	36188
animals	36188
injections	36210
OEG-LacZ or ` medium	36226
Ruitenberg et al. , 2003	36279
Ruitenberg	36279
et al.	36290
2003	36298
p75 labelling	36313
adjacent immunoreacted spinal cord sections	36330
regions containing intense NT-3 mRNA expression	36396
regions	36396
intense NT-3 mRNA expression	36415
Behavioural analysis	36445
field testing	36471
Behavioural analysis	36485
OEG-grafted rats during over-ground locomotion -LRB- BBB score -RRB-	36509
OEG-grafted rats	36509
over-ground locomotion -LRB- BBB score -RRB-	36533
over-ground locomotion	36533
BBB score	36557
detectable changes	36583
control	36607
animals over the analysed period -LRB- 10 weeks -RRB-	36633
animals	36633
the analysed period -LRB- 10 weeks -RRB-	36646
the analysed period	36646
10 weeks	36667
Gait	36678
plantar steps	36734
there	36752
only occasional coordination between fore - and hindlimbs	36762
only occasional coordination between fore	36762
only occasional coordination	36762
fore	36799
hindlimbs	36809
A steady rating of 12	36820
A steady rating	36820
12	36839
all animals	36857
week 4 onwards	36874
Movement analysis	36890
pellet retrieval success ratings Body rotation after surgery	36912
pellet retrieval success ratings Body rotation	36912
surgery	36965
most experimental animals	36989
they	37018
difficulties in raising the right forelimb	37027
difficulties	37027
the right forelimb	37051
The head and shoulders	37071
The head	37071
shoulders	37084
anticlockwise motion	37108
90 °	37136
the right forelimb	37151
the air	37184
The forepaw	37193
the food pellet	37228
the limb	37248
it	37280
the inner edge of the shelf	37291
the inner edge	37291
the shelf	37309
Fig. 2A	37337
Components such as grasp , supination and release	37346
Components	37346
grasp , supination and release	37365
Pre-surgery baseline level of success	37418
Pre-surgery baseline level	37418
success	37448
18 -- 23 pellets eaten in 2 min	37457
18 -- 23	37457
pellets	37463
2 min	37480
P > 0.05	37520
P	37520
> 0.05	37522
>	37522
0.05	37524
the experimental groups	37538
Movement rating	37563
2 weeks	37589
surgery -LRB- week 3 -RRB-	37607
surgery	37607
week 3	37616
pellet retrieval	37630
all groups -LRB- 0 -- 6 pellets eaten in 2 min ; see Fig. 2B -RRB-	37676
all groups	37676
0 -- 6 pellets eaten in 2 min ; see Fig. 2B	37688
0 -- 6	37688
pellets	37692
2 min ; see Fig. 2B	37709
2 min	37709
Fig. 2B	37720
All experimental animals	37730
12 weeks	37773
surgery	37788
success ratings	37812
all groups -LRB- 9 -- 25 pellets / 2 min -RRB-	37848
all groups	37848
9 -- 25 pellets / 2 min	37860
9 -- 25 pellets /	37860
9	37860
25 pellets	37862
2 min	37874
Repeated measures ANOVA	37882
Repeated measures	37882
ANOVA	37900
a statistically significant improvement in animals ' success ratings	37913
a statistically significant improvement	37913
animals ' success ratings	37956
animals '	37956
time -LRB- P < 0.001 -RRB-	37986
time	37986
P < 0.001	37992
P	37992
< 0.001	37994
<	37994
0.001	37996
the experimental groups -LRB- P = 0.110 -RRB-	38020
the experimental groups	38020
P	38045
0.110	38049
Pre-surgery movement ratings for all experimental animals	38057
Pre-surgery movement ratings	38057
all experimental animals	38090
0 and 2	38135
normal forelimb performance	38155
Movement ratings	38184
all animals	38231
surgery	38249
abnormalities	38269
forelimb function	38286
the test period -LRB- 11.3 -- 15.2 ; Fig. 2C -RRB-	38346
the test period	38346
11.3	38363
15.2 ; Fig. 2C	38368
15.2	38368
Fig. 2C	38374
Repeated measures ANOVA	38384
Repeated measures	38384
ANOVA	38402
no statistically significant changes	38415
postsurgery movement rating over time -LRB- P = 0.503 -RRB-	38455
postsurgery movement rating	38455
time -LRB- P = 0.503 -RRB-	38488
time	38488
P	38494
0.503	38498
differences between the experimental groups -LRB- P = 0.506 -RRB-	38509
differences	38509
the experimental groups -LRB- P = 0.506 -RRB-	38529
the experimental groups	38529
P	38554
0.506	38558
Pellet retrieval	38566
movement ratings	38590
Behaviour of all animals , regardless of experimental treatment	38607
Behaviour	38607
all animals , regardless of experimental treatment	38620
all animals	38620
experimental treatment	38647
a pattern of improvement in pellet retrieval success rating	38686
a pattern	38686
improvement in pellet retrieval success rating	38699
improvement	38699
pellet retrieval success rating	38714
corresponding restoration	38754
skilled forelimb use	38783
animal no. 18 ; Fig. 2D , left panel	38820
animal no.	38820
18 ; Fig. 2D ,	38831
18	38831
Fig. 2D	38835
panel	38849
An exception to this pattern	38857
An exception	38857
this pattern	38873
OEG-NT-3-transplated rat 11	38899
a concurrent loss of both success and movement ratings over the first 7 weeks	38947
a concurrent loss	38947
both success and movement ratings over the first 7 weeks	38968
both success and movement ratings	38968
the first 7 weeks	39007
a simultaneous improvement of these parameters	39044
a simultaneous improvement	39044
these parameters	39074
week	39096
7 to 9 -LRB- Fig. 2D , right panel -RRB-	39101
7 to 9	39101
Fig. 2D	39109
right panel	39118
week 9	39138
the movement rating	39155
pellet retrieval	39210
Histological analysis Anterograde CST tracing Both dorso-medial CST projections	39249
Histological analysis Anterograde CST	39249
Both	39295
dorso-medial CST projections	39300
either BDA-G or BDA-R	39348
BDA-G	39355
BDA-R	39364
illustrated -LRB- see diagram , Fig. 3A -RRB-	39373
illustrated	39373
diagram , Fig. 3A	39390
Normal , uninjured Fischer 344 rats -LRB- n = 2 -RRB-	39409
Normal , uninjured Fischer 344 rats	39409
n	39445
2	39449
the tracing procedure -LRB- Fig. 3B and C -RRB-	39474
the tracing procedure	39474
Fig. 3B and C	39497
Fig. 3B	39497
C	39509
The border between the two projections	39513
The border	39513
the two projections	39532
numbers of axons -LRB- < 5 % -RRB-	39590
numbers	39590
axons -LRB- < 5 % -RRB-	39601
axons	39601
< 5 %	39608
<	39608
5 %	39609
the injected cortical hemisphere	39642
CST projections in experimental animals	39676
CST projections	39676
experimental animals	39695
processing	39756
50 sagittal sections -LRB- 40 µm -RRB-	39769
50 sagittal sections	39769
40 µm	39791
rat	39816
8 -- 10 of which	39821
8 -- 10	39821
BDA-G-labelled fibres	39845
all operated rats	39871
all	39871
rats	39884
CST axons	39890
enlarged , dystrophic ends and sprouts	39914
the lesion site	39969
the BDA-Glabelled CST	39999
wider	40031
more proximal undamaged parts	40050
Virtually no BDA-G-labelled fibres	40081
the lesion area itself	40129
the lesion area	40129
distal spinal cord in vehicleinjected controls , or OEG	40158
distal spinal cord	40158
vehicleinjected controls , or	40180
vehicleinjected controls	40180
OEG-LacZ-implanted rats -LRB- Fig. 3D -RRB-	40218
OEG-LacZ-implanted rats	40218
Fig. 3D	40243
Immunohistochemistry for GFAP	40253
Immunohistochemistry	40253
GFAP	40278
the presence of hypertrophic astrocytes	40290
the presence	40290
hypertrophic astrocytes	40306
a 200 -- 300 µm radius of the damaged area -LRB- Fig. 3E -RRB-	40337
a 200	40337
300 µm radius of the damaged area -LRB- Fig. 3E -RRB-	40343
300 µm radius	40343
the damaged area -LRB- Fig. 3E -RRB-	40360
the damaged area	40360
Fig. 3E	40378
lesioned BDA-G-labelled CST axons abutting the proximal border of the glial scar	40393
lesioned BDA-G-labelled CST axons	40393
the proximal border of the glial scar	40436
the proximal border	40436
the glial scar	40459
all transplanted animals	40478
the phenotypic appearance and purity	40504
primary OEG preparations	40544
the olfactory bulbs of adult Fischer 344 rats	40585
the olfactory bulbs	40585
adult Fischer 344 rats	40608
transplantation	40655
OEG	40681
S100 -LRB- not shown -RRB- , GFAP and p75 -LRB- Fig. 4A -RRB-	40709
S100 -LRB- not shown -RRB-	40709
S100	40709
GFAP and p75 -LRB- Fig. 4A -RRB-	40727
GFAP and p75	40727
Fig. 4A	40741
The purity of all cultures used for transplantation purposes	40751
The purity	40751
all cultures used for transplantation purposes	40765
all cultures	40765
transplantation purposes	40787
between 95 and 98 %	40816
the ratio of p75-stained cells	40855
the ratio	40855
p75-stained cells	40868
the total cell number	40889
12 weeks	40918
numerous p75 - immunoreactive cells	40928
numerous p75	40928
immunoreactive cells	40942
the damaged area of all OEG-transplanted animals -LRB- Fig. 4B -RRB-	40980
the damaged area	40980
all OEG-transplanted animals -LRB- Fig. 4B -RRB-	41000
all OEG-transplanted animals	41000
Fig. 4B	41030
Many fewer cells	41040
most	41058
host Schwann cells	41072
the injured cord -LRB- Ruitenberg et al. , 2003 -RRB-	41108
the injured cord	41108
Ruitenberg	41126
et al. , 2003	41137
et al.	41137
2003	41145
vehicle-injected controls	41166
four out of the five animals analysed receiving OEG-NT-3 implants	41205
four	41205
the five animals	41217
OEG-NT-3 implants	41253
BDA-G-labelled fibres	41278
the proximal mass	41315
lesioned CST axons	41336
the lesion site	41363
more distal parts of the spinal cord as far as	41388
more distal parts	41388
the spinal cord as far as	41409
the spinal cord	41409
at least 1 cm -LRB- Fig. 4C -RRB-	41435
at least 1 cm	41435
Fig. 4C	41450
These distal CST axons	41460
distribution	41501
a beaded appearance and uneven trajectory -LRB- Fig. 4D -RRB-	41519
a beaded appearance	41519
uneven trajectory -LRB- Fig. 4D -RRB-	41543
uneven trajectory	41543
Fig. 4D	41562
regeneratingCSTfibres -LRB- Steward et al. , 2003 -RRB-	41617
regeneratingCSTfibres	41617
Steward	41640
et al. , 2003	41648
et al.	41648
2003	41656
the transverse sections	41666
no BDA-G fibres	41691
1 cm	41717
the lesion site in any of the vehicle-injected , OEG	41732
the lesion site	41732
any of the vehicle-injected , OEG	41751
any	41751
the vehicle-injected	41758
Fig. 4E	41813
Distal BDA-G-labelled CST axons	41823
this level in four of the five OEG-NT-3	41878
this level	41878
four of the five OEG-NT-3	41892
four	41892
the five OEG-NT-3	41900
transplanted animals -LRB- Fig. 4F -RRB-	41918
transplanted animals	41918
Fig. 4F	41940
average	41953
≈ 9 % of proximally labelled fibres	41962
≈ 9 %	41962
proximally labelled fibres	41969
at least 1 cm	42006
the lesion site -LRB- see later -RRB- , which was the maximum distance measured	42030
the lesion site -LRB- see later -RRB-	42030
the lesion site	42030
the maximum distance measured	42069
the maximum distance	42069
These labelled axons	42100
These	42100
axons	42115
a localized area of white matter	42170
a localized area	42170
white matter	42190
the latter organization being	42204
an incomplete CST lesion	42253
Quantification of dorsal CST	42279
Quantification	42279
dorsal CST	42297
Labelled CST fibres in sagittal sections	42314
Labelled CST fibres	42314
sagittal sections	42337
signal fluorescence	42384
four distances in a rostral	42407
four distances	42407
a rostral	42425
caudal direction across the lesion site -LRB- Fig. 5A and B -RRB-	42438
caudal direction	42438
the lesion site -LRB- Fig. 5A and B -RRB-	42462
the lesion site	42462
Fig. 5A and B	42479
Fig. 5A	42479
B	42491
These values	42495
each experimental group , i.e. vehicle-injected , OEG -	42531
each experimental group	42531
i.e. vehicle-injected , OEG	42556
i.e.	42556
vehicle-injected , OEG	42561
vehicle-injected	42561
OEG-LacZ - and OEG-NT-3 - transplanted rats -LRB- Fig. 5C -RRB-	42585
OEG-LacZ	42585
OEG-NT-3 - transplanted rats -LRB- Fig. 5C -RRB-	42599
OEG-NT-3	42599
transplanted rats -LRB- Fig. 5C -RRB-	42609
transplanted rats	42609
Fig. 5C	42628
The fluorescence intensity of CST fibres	42638
The fluorescence intensity	42638
CST fibres	42668
the lesion area -LRB- -1.0 mm -RRB-	42705
the lesion area	42705
-1.0 mm	42722
the centre -LRB- 0 mm -RRB-	42754
the centre	42754
0 mm	42766
more distal parts of the lesion -LRB- + 0.5 and + 1.0 mm -RRB-	42776
more distal parts	42776
the lesion -LRB- + 0.5 and + 1.0 mm -RRB-	42797
the lesion	42797
+ 0.5 and + 1.0	42809
0.5 and	42811
1.0	42821
mm	42825
There	42830
a trend	42840
increased numbers	42856
distal CST axons	42877
the OEG-NT-3-implanted animal group	42897
consistently higher signal fluorescence	42942
the lesion centre	42985
more caudal parts	43007
the spinal cord than all other experimental groups -LRB- Fig. 5C -RRB-	43028
the spinal cord	43028
all other experimental groups -LRB- Fig. 5C -RRB-	43049
all other experimental groups	43049
Fig. 5C	43080
Simple contrast tests	43090
statistical significance	43124
increased fluorescence measures in the OEGNT - 3 group	43152
increased fluorescence measures	43152
the OEGNT - 3 group	43187
the OEGNT	43187
3 group	43198
both + 0.5 mm -LRB- P = 0.085 -RRB-	43226
both	43226
0.5 mm	43233
P	43241
0.085	43245
+	43256
1.0 mm -LRB- P = 0.066 -RRB-	43258
1.0 mm	43258
P	43266
0.066	43270
its control , the OEG-LacZ group	43296
its control	43296
the OEG-LacZ group	43309
transverse sections	43332
the density	43353
CST fibres within both BDA-G	43368
CST fibres	43368
both BDA-G	43386
BDA-R -LRB- uninjured -RRB- labelled projections at 1 cm distal to the injury	43412
BDA-R -LRB- uninjured -RRB-	43412
BDA-R	43412
projections	43439
1 cm distal to the injury	43454
1 cm	43454
the injury	43469
a percentage of total label -LRB- measured 1 cm proximal to the injury -RRB-	43497
a percentage	43497
total label	43513
1 cm	43535
the injury	43552
vehicle-injected control animals	43568
signal fluorescence 1 cm distal to the injury site	43602
signal fluorescence	43602
1 cm	43622
the injury site	43637
only 0.66 6 0.2 % -LRB- mean ± SEM ; n = 5 -RRB- of the proximal signal	43668
only 0.66 6 0.2 %	43668
only 0.66	43668
mean ± SEM ; n = 5	43686
mean ± SEM	43686
n = 5	43698
n	43698
5	43702
the proximal signal	43708
Similar values	43729
the OEG -	43759
the OEG	43759
1.5 ± 0.7 % ; n = 5	43769
1.5 ± 0.7 % ; n	43769
1.5 ± 0.7 %	43769
1.5	43769
0.7 %	43775
n	43781
= 5	43783
OEG-LacZ	43792
1.1 ± 0.2 % ; n = 5	43803
1.1 ± 0.2 % ; n	43803
1.1 ± 0.2 %	43803
1.1	43803
0.2 %	43809
n	43815
= 5	43817
groups	43835
OEG-NT-3-transplanted animals	43858
much higher values of ≈ 9 % of the proximal label	43889
much higher values	43889
≈ 9 % of the proximal label	43911
≈ 9 %	43911
the proximal label	43918
1 cm	43947
the injury site	43958
9.1 ± 1.43 % ; n = 5 ; Fig. 5D	43975
9.1 ± 1.43 % ; n = 5 ; Fig.	43975
9.1 ± 1.43 %	43975
9.1	43975
1.43 %	43981
n = 5 ; Fig.	43988
n = 5	43988
n	43988
5	43992
Fig.	43995
5D	44000
analysis	44024
a significant overall treatment effect	44042
the experimental groups -LSB- F -LRB- 3,20 -RRB- = 15.45	44089
the experimental groups -LSB- F -LRB- 3,20 -RRB-	44089
the experimental groups -LSB- F	44089
3,20	44116
15.45	44124
P = 0.0001	44131
P	44131
0.0001	44135
Further analysis	44144
no statistical differences	44168
groups	44203
vehicle injections , OEG or OEG-LacZ transplants	44224
P > 0.57	44273
P	44273
> 0.57	44275
>	44275
0.57	44277
the distal CST label in OEG-NT-3-transplanted animals	44288
the distal CST label	44288
OEG-NT-3-transplanted animals	44312
other groups -LRB- P < 0.0005 -RRB-	44382
other groups	44382
P < 0.0005	44396
P	44396
< 0.0005	44398
<	44398
0.0005	44400
There	44409
no evidence	44419
progressive changes in BDA-R-labelled fibre densities or compensatory growth	44434
progressive changes	44434
BDA-R-labelled fibre densities or compensatory growth	44457
BDA-R-labelled fibre densities	44457
compensatory growth	44491
the BDA-G projection	44516
termination areas	44541
the injury site	44569
OEG transplants	44586
tissue sparing Spinal tissue sparing	44610
tissue	44610
Spinal tissue sparing	44625
the damaged area	44667
cysts , degenerate tissue and transplanted OEG	44695
cysts	44695
degenerate tissue and transplanted OEG	44702
degenerate tissue	44702
transplanted OEG	44724
a 2.5 mm long spinal cord segment -LRB- Fig. 6A -RRB-	44749
a 2.5 mm long spinal cord segment	44749
2.5 mm	44751
Fig. 6A	44784
the vehicle-injected group	44797
75.2 ± 4.8 % -LRB- mean ± SEM , n = 5 -RRB- of the spinal cord segment examined	44825
75.2 ± 4.8 % -LRB- mean ± SEM , n = 5 -RRB-	44825
75.2 ± 4.8 %	44825
75.2	44825
4.8 %	44832
mean ± SEM , n = 5	44838
mean ± SEM	44838
n = 5	44850
n	44850
5	44854
the spinal cord segment examined	44860
the spinal cord segment	44860
contrast	44908
significantly more -LRB- P < 0.006 -RRB- spinal tissue	44918
P < 0.006	44938
P	44938
< 0.006	44940
<	44940
0.006	44942
OEG -	44977
OEG	44977
87.7 ± 1.0 % ; n = 5	44983
87.7 ± 1.0 % ; n	44983
87.7 ± 1.0 %	44983
87.7	44983
1.0 %	44990
n	44996
= 5	44998
OEG-LacZ	45004
87.5 ± 0.9 % ; n = 5	45015
87.5 ± 0.9 % ; n	45015
87.5 ± 0.9 %	45015
87.5	45015
0.9 %	45022
n	45028
= 5	45030
OEG-NT-3	45039
87.7 ± 0.8 % ; n = 5	45050
87.7 ± 0.8 % ; n	45050
87.7 ± 0.8 %	45050
87.7	45050
0.8 %	45057
n	45063
= 5	45065
groups	45080
Mean cyst area and number	45088
Mean cyst area	45088
number	45107
experimental groups	45135
P > 0.05 ; Fig. 6B	45156
P	45156
> 0.05 ; Fig. 6B	45158
> 0.05	45158
>	45158
0.05	45160
Fig. 6B	45166
The amount of degenerate tissue	45176
The amount	45176
degenerate tissue	45190
all transplanted animals -LRB- P < 0.004 ; Fig. 6C -RRB-	45239
all transplanted animals	45239
P < 0.004 ; Fig. 6C	45265
P	45265
< 0.004 ; Fig. 6C	45267
< 0.004	45267
<	45267
0.004	45269
Fig. 6C	45276
all OEG-transplanted animals	45299
greater p75 immunoreactivity	45332
the grafted area	45364
medium-injected control rats -LRB- P < 0.0001 ; Fig. 6D -RRB-	45386
medium-injected control rats	45386
P < 0.0001 ; Fig. 6D	45416
P	45416
< 0.0001 ; Fig. 6D	45418
< 0.0001	45418
<	45418
0.0001	45420
Fig. 6D	45428
there	45444
no significant difference between OEG and OEG-LacZ groups -LRB- P = 0.78 -RRB-	45454
no significant difference	45454
OEG and OEG-LacZ groups -LRB- P = 0.78 -RRB-	45488
OEG and OEG-LacZ groups	45488
P	45513
0.78	45517
the p75 - positive area in the OEG-NT-3 group	45524
the p75	45524
positive area in the OEG-NT-3 group	45533
positive area	45533
the OEG-NT-3 group	45550
all other OEG-transplanted groups	45599
P < 0.004	45634
P	45634
< 0.004	45636
<	45636
0.004	45638
This increase	45646
improved survival	45675
proliferation of engineered donor cells -LRB- Bianco et al. , 2004 -RRB-	45700
proliferation	45700
engineered donor cells -LRB- Bianco et al. , 2004 -RRB-	45717
engineered donor cells	45717
Bianco	45741
et al. , 2004	45748
et al.	45748
2004	45756
host	45787
Schwann cell invasion in this group -LRB- Ramer et al. , 2004 -RRB-	45792
Schwann cell invasion	45792
this group -LRB- Ramer et al. , 2004 -RRB-	45817
this group	45817
Ramer	45829
et al. , 2004	45835
et al.	45835
2004	45843
an additional series of in vitro experiments	45853
an additional series	45853
experiments	45886
we	45899
the mitogenic effects	45910
NT-3 on adult OEG cultures via BrdU incorporation	45953
NT-3	45953
adult OEG cultures via BrdU incorporation	45961
adult OEG cultures	45961
BrdU incorporation	45984
Cells	46004
serum-free -LRB- CD -RRB- or mitogen-containing -LRB- DF-10S -RRB- medium.We	46031
serum-free -LRB- CD -RRB-	46031
serum-free	46031
mitogen-containing -LRB- DF-10S -RRB- medium.We	46048
DF-10S	46068
no evidence	46091
transduction of cells with AdV-NT-3	46108
transduction	46108
cells with AdV-NT-3	46124
cells	46124
AdV-NT-3	46135
increased proliferation	46156
purified adult OEG that were obtained from the olfactory bulb nerve layer	46183
purified adult OEG	46183
the olfactory bulb nerve layer	46226
Additional experiments , adding recombinant NT-3 to OEG cultures ,	46258
Additional experiments	46258
recombinant NT-3	46289
OEG cultures	46309
no mitogenic effects of this neurotrophin	46335
no mitogenic effects	46335
this neurotrophin	46359
any concentration -LRB- Fig. 7A -- C -RRB-	46380
any concentration	46380
Fig. 7A -- C	46399
Fig. 7A	46399
C	46407
Further analysis of total cell numbers after plating	46411
Further analysis	46411
total cell numbers after plating	46431
total cell numbers	46431
plating	46456
any effects of NT-3	46481
any effects	46481
NT-3	46496
OEG viability	46504
the 2 day time period	46533
DRGs	46601
the presence of NT-3	46625
the presence	46625
NT-3	46641
biological activity of this recombinant neurotrophin	46658
biological activity	46658
this recombinant neurotrophin	46681
addition to robust neurite outgrowth	46727
addition	46727
robust neurite outgrowth	46739
there	46765
Schwann cell dispersal	46790
the explants	46818
Fig. 7C and D	46832
Fig. 7C	46832
D	46844
The latter observation	46848
an effect	46890
NT-3 on Schwann cell migration and chemokinesis -LRB- Maniwa et al. , 2003 -RRB-	46903
NT-3 on Schwann cell migration	46903
NT-3	46903
Schwann cell migration	46911
chemokinesis -LRB- Maniwa et al. , 2003 -RRB-	46938
chemokinesis	46938
Maniwa	46952
et al. , 2003	46959
et al.	46959
2003	46967
Discussion We report the effects of genetically	46975
Discussion	46975
We	46986
the effects	46996
OEG transplants	47032
spinal cord tissue sparing and CST sprouting/regeneration	47051
cervical injury in rats	47115
cervical injury	47115
rats	47134
spinal cord tissue	47159
all OEG-transplanted animals	47192
vehicle-injected controls	47235
Qualitative and quantitative histological analysis of BDA-G-labelled CST axons	47262
Qualitative and quantitative histological analysis	47262
BDA-G-labelled CST axons	47316
OEG implants	47353
NT-3	47388
longdistance maintenance/regrowth	47401
these axons for up to at least 1 cm distal to the injury site	47438
these axons	47438
up to at least 1 cm distal to the injury site	47454
up to at least 1 cm	47454
at least 1	47460
the injury site	47484
Behavioural analysis	47501
some post-lesion recovery	47531
there	47561
no significant differences between experimental groups	47572
no significant differences	47572
experimental groups	47607
no changes	47631
the pattern and distribution	47655
uninjured BDA-R-labelled CST axons distal from the lesion site	47687
uninjured BDA-R-labelled CST axons	47687
the lesion site	47734
our results	47751
compensatory involvement of intraspinal circuitry	47772
compensatory involvement	47772
intraspinal circuitry	47800
supraspinal pathways	47846
post-lesion recovery	47870
OEG-implanted rats	47892
spinal tissue -LRB- 10 -- 15 % -RRB- at 12 weeks	47941
spinal tissue -LRB- 10 -- 15 % -RRB-	47941
spinal tissue	47941
10 -- 15 %	47956
10	47956
15 %	47959
12 weeks	47967
injury	47982
vehicle-injected controls	48003
This	48030
the preservation of white matter tracts	48044
the preservation	48044
white matter tracts	48064
intraspinal neurons	48088
the area	48111
the primary injury site	48133
functional adaptation	48184
the injury	48212
These findings	48224
previous reports	48259
OEG	48289
spinal cord tissue sparing	48318
Takami	48346
et al. , 2002	48353
et al.	48353
2002	48361
Plant et al. , 2003	48367
Plant	48367
et al. , 2003	48373
et al.	48373
2003	48381
Ruitenberg et al. , 2003	48387
Ruitenberg	48387
et al. , 2003	48398
et al.	48398
2003	48406
Verdu et al. , 2003	48412
Verdu	48412
et al. , 2003	48418
et al.	48418
2003	48426
Ramer et al. , 2004	48432
Ramer	48432
et al. , 2004	48438
et al.	48438
2004	48446
transplanted animals	48456
many of the cells present at the site of engraftment	48478
many	48478
the cells present at the site of engraftment	48486
the cells	48486
the site of engraftment	48507
the site	48507
engraftment	48519
p75	48536
This population	48550
the lesion	48574
the rostral	48590
caudal extents of intact spinal cord	48605
caudal extents	48605
intact spinal cord	48623
a cellular substrate	48653
growing axons towards the opposing end of the spinal cord	48678
growing axons	48678
the opposing end of the spinal cord	48700
the opposing end	48700
the spinal cord	48720
a proportion of these p75-positive cells	48746
a proportion	48746
these p75-positive cells	48762
host -LRB- non-myelinating -RRB- Schwann cells	48794
host	48794
non-myelinating	48800
Schwann cells	48817
Takami	48832
et al. , 2002	48839
et al.	48839
2002	48847
Ruitenberg et al. , 2003	48853
Ruitenberg	48853
et al. , 2003	48864
et al.	48864
2003	48872
Boyd et al. , 2004	48878
Boyd	48878
et al. , 2004	48883
et al.	48883
2004	48891
Ramer et al. , 2004	48897
Ramer	48897
et al. , 2004	48903
et al.	48903
2004	48911
previous work	48918
the fate	48942
green fluorescent protein	48954
GFP	48981
OEG in similar transection models	48996
OEG	48996
similar transection models	49003
grafted OEG	49043
Ruitenberg et al. , 2002 ; Sasaki et al. , 2004	49065
Ruitenberg	49065
et al. , 2002 ; Sasaki et al. , 2004	49076
et al. , 2002	49076
et al.	49076
2002	49084
Sasaki et al. , 2004	49090
Sasaki	49090
et al. , 2004	49097
et al.	49097
2004	49105
a significant proportion	49123
these p75 - immunoreactive cells -LRB- Ruitenberg et al. , 2002a -RRB-	49151
these p75	49151
immunoreactive cells	49162
Ruitenberg	49184
et al. , 2002a	49195
et al.	49195
2002a	49203
both vehicle-injected and OEG-implanted animal groups	49214
the majority of lesioned CST axons	49269
the majority	49269
lesioned CST axons	49285
enlarged bulbous ends	49311
the proximal edge of the lesion	49339
the proximal edge	49339
the lesion	49360
rats	49375
vehicle injections or control implants	49394
OEG and OEG-LacZ groups	49434
OEG	49434
OEG-LacZ groups	49442
CST axons	49460
the injury site	49494
agreement with Takami et al. -LRB- 2002 -RRB- but in contrast	49523
agreement	49523
Takami et al. -LRB- 2002 -RRB-	49538
Takami et al.	49538
Takami	49538
et al.	49545
2002	49553
contrast	49566
data	49578
other groups	49595
Li	49609
et al. , 1998	49612
et al.	49612
1998	49620
Ramon-Cueto et al. , 2000	49626
Ramon-Cueto	49626
et al. , 2000	49638
et al.	49638
2000	49646
Nash et al. , 2002	49652
Nash	49652
et al. , 2002	49657
et al.	49657
2002	49665
Keyvan-Fouladi et al. , 2003	49671
Keyvan-Fouladi	49671
et al. , 2003	49686
et al.	49686
2003	49694
It	49701
these discrepancies	49730
true differences in outcomes	49760
true differences	49760
outcomes	49780
they	49800
experimental differences in lesion procedures , OEG preparation protocols	49825
experimental differences	49825
lesion procedures , OEG preparation protocols	49853
lesion procedures	49853
OEG preparation protocols	49872
purity	49916
Only in OEG-NT-3 transplanted rats	49924
Only	49924
OEG-NT-3 transplanted rats	49932
there	49963
evidence of CST	49969
evidence	49969
CST	49981
0.5 and 1 mm distal to the lesion epicentre	49995
0.5 and 1 mm	49995
the lesion epicentre	50018
others	50040
similar effects of NT-3	50062
similar effects	50062
NT-3	50081
CST axons	50089
Schnell	50100
et al. , 1994 ; Senut et al. , 1995 ; Grill et al. , 1997 ; Blits et al. , 2000	50108
et al. , 1994	50108
et al.	50108
1994	50116
Senut et al. , 1995	50122
Senut	50122
et al. , 1995	50128
et al.	50128
1995	50136
Grill et al. , 1997	50142
Grill	50142
et al. , 1997	50148
et al.	50148
1997	50156
Blits et al. , 2000	50162
Blits	50162
et al. , 2000	50168
et al.	50168
2000	50176
Significantly more BDA-G-labelled CST fibres	50183
1 cm distal to the lesion in the OEG-NT-3 group	50248
1 cm	50248
the lesion in the OEG-NT-3 group	50263
the lesion	50263
the OEG-NT-3 group	50277
These axons	50297
a beaded appearance -LRB- Li et al. , 1997 -RRB-	50313
a beaded appearance	50313
Li	50334
et al. , 1997	50337
et al.	50337
1997	50345
the damaged area	50365
the more ventral portions of the lesion and implantation site	50390
the more ventral portions	50390
the lesion and implantation site	50419
Further	50453
the majority of BDA-G-labelled CST axons	50471
the majority	50471
BDA-G-labelled CST axons	50487
a more scattered , defasciculated pattern	50529
an uneven trajectory along the rostro-caudal axis of the denervated spinal cord	50575
an uneven trajectory	50575
the rostro-caudal axis of the denervated spinal cord	50602
the rostro-caudal axis	50602
the denervated spinal cord	50628
the	50628
spinal cord	50643
Such features	50656
axonal regrowth	50697
normal CST organization -LRB- Steward et al. , 2003 -RRB-	50718
normal CST organization	50718
Steward	50743
et al. , 2003	50751
et al.	50751
2003	50759
morphological criteria	50775
true axonal regeneration	50828
partial spinal cord transection models	50884
an important area of debate	50931
an important area	50931
debate	50952
our study	50963
there	50974
a comparable amount of preserved spinal tissue	50984
a comparable amount	50984
preserved spinal tissue	51007
all OEG transplant paradigms	51034
the increased number of distal CST axons in the OEG-NT-3 group	51080
the increased number	51080
distal CST axons	51104
the OEG-NT-3 group	51124
a difference in overall tissue sparing	51158
a difference	51158
overall tissue sparing	51174
Regeneration of at least some CST fibres	51198
Regeneration	51198
at least some CST fibres	51214
it	51267
NT-3 released from	51292
NT-3	51292
OEGhada	51322
selective andspecific effectonprotectingcompromised CST axons	51330
subsequent secondary degeneration	51397
All experimental animals	51432
skilled forelimb reaching	51473
skilled forelimb	51473
They	51500
severe impairment	51512
injury followed by partial recovery	51548
injury	51548
partial recovery	51567
Success ratings in transplanted animals	51585
Success ratings	51585
transplanted animals	51604
controls	51659
the period	51673
analysis	51687
the results of Nash	51718
the results	51718
Nash	51733
et al.	51738
2002	51746
methylprednisolone administration	51766
OEG transplantation	51805
Our results	51826
the original findings	51856
Schrimsher and Reier -LRB- 1993 -RRB-	51881
Schrimsher and Reier	51881
1993	51903
a recovery	51924
the pellet retrieval task performance over time	51938
the pellet retrieval task performance	51938
time	51981
a C4 cervical lesion	51992
Movement ratings	52014
the testing period	52065
the experimental groups	52111
This	52136
increasing success in the forelimb reaching task over time	52151
increasing success	52151
the forelimb reaching task over time	52173
the forelimb	52173
task over time	52195
task	52195
time	52205
no parallel improvement in animals ' movements	52215
no parallel improvement	52215
animals ' movements	52242
animals '	52242
the food pellets	52274
our findings	52299
the improvements in pellet retrieval	52325
the improvements	52325
pellet retrieval	52345
spinal or supraspinal compensatory mechanisms	52373
spinal	52373
supraspinal compensatory mechanisms	52383
adaptation	52432
recovery of skilled movements due to anatomical CST regeneration	52456
recovery	52456
skilled movements due to anatomical CST regeneration	52468
skilled movements	52468
anatomical CST regeneration	52493
Closer inspection of movement ratings -LRB- Whishaw et al. , 1993 -RRB-	52522
Closer inspection of movement ratings	52522
Closer inspection	52522
movement ratings	52543
Whishaw	52561
et al. , 1993	52569
et al.	52569
1993	52577
specific task components	52597
unilateral CST lesions	52639
These	52663
supination	52678
and release of the food pellet	52699
release of the food pellet	52703
release	52703
the food pellet	52714
Impairments of distal forelimb muscle	52731
Impairments	52731
distal forelimb muscle	52746
similar cervical lesions	52804
the dorsal columns	52832
the CST	52864
Schrimsher and Reier	52873
1993 ; Whishaw et al. , 1993 ; McKenna and Whishaw , 1999 ; Raineteau et al.	52895
1993	52895
Whishaw et al. , 1993 ; McKenna and Whishaw , 1999 ; Raineteau et al.	52901
Whishaw	52901
et al. , 1993 ; McKenna and Whishaw , 1999 ; Raineteau et al.	52909
et al. , 1993	52909
et al.	52909
1993	52917
McKenna and Whishaw , 1999	52923
McKenna and Whishaw	52923
1999	52944
Raineteau et al.	52950
Raineteau	52950
et al.	52960
2001	52968
It	52975
future studies involving behavioural analysis	53005
future studies	53005
behavioural analysis	53030
the exact movements	53067
damage	53110
specific spinal motor pathways	53120
the present study	53155
a task that may have been more sensitive to a CST lesion in rats	53174
a task	53174
a CST lesion	53218
rats	53234
one requiring supination , grasping	53248
one	53248
supination	53262
release	53287
the forepaw	53298
e.g. Galea and Darian-Smith	53311
e.g. Galea	53311
Darian-Smith	53326
1997 ; Ballermann et al. , 2001	53340
1997	53340
Ballermann et al. , 2001	53346
Ballermann	53346
et al. , 2001	53357
et al.	53357
2001	53365
Several mechanisms , other than axonal regeneration ,	53372
Several mechanisms	53372
other than axonal regeneration	53392
other	53392
axonal regeneration	53403
functional recovery	53461
spinal cord injury	53487
e.g. Houweling et al.	53507
1998	53530
Jakeman	53536
et al. , 1998	53544
et al.	53544
1998	53552
von Meyenburg et al. , 1998	53558
von Meyenburg	53558
et al. , 1998	53572
et al.	53572
1998	53580
Tuszynski et al. , 1999	53586
Tuszynski	53586
et al. , 1999	53596
et al.	53596
1999	53604
Corbetta et al. , 2002	53610
Corbetta	53610
et al. , 2002	53619
et al.	53619
2002	53627
Gomez-Pinilla et al. , 2002	53633
Gomez-Pinilla	53633
et al. , 2002	53647
et al.	53647
2002	53655
Blits et al. , 2003	53661
Blits	53661
et al. , 2003	53667
et al.	53667
2003	53675
Ruitenberg et al. , 2003	53681
Ruitenberg	53681
et al. , 2003	53692
et al.	53692
2003	53700
Bareyre et al.	53706
Bareyre	53706
et al.	53714
2004	53722
mechanisms of action	53738
mechanisms	53738
action	53752
functional compensation	53767
pathways	53812
the stimulation of ` central pattern generators '	53822
the stimulation	53822
central pattern generators '	53842
pattern generators '	53850
simple motor programs	53871
the distal spinal cord	53901
plasticity	53937
the spinal cord or higher brain centres	53959
the spinal cord	53959
higher brain centres	53978
plasticity	54024
remaining tissue , surrounding a partial lesion	54049
remaining tissue	54049
a partial lesion	54079
the functional roles of the damaged motor tracts	54110
the functional roles	54110
the damaged motor tracts	54134
recovery of movement	54179
recovery	54179
movement	54191
our study	54204
the rubrospinal tract	54215
many functional similarities to the CST -LRB- Kennedy , 1990 -RRB-	54248
many functional similarities	54248
the CST	54280
Kennedy	54289
1990	54298
fine motor control -LRB- Whishaw et al. , 1990 -RRB-	54323
fine motor control	54323
Whishaw	54343
et al. , 1990	54351
et al.	54351
1990	54359
a role	54386
it	54400
the CST	54434
a study by Weidner et al. -LRB- 2001 -RRB-	54458
a study by Weidner et al.	54458
a study by Weidner	54458
a study	54458
Weidner	54469
et al.	54477
2001	54485
spontaneous	54500
the ventral CST	54525
ablation of the dorsal	54547
ablation	54547
the dorsal	54559
CST , which correlated with improvements in forelimb function	54570
CST	54570
improvements	54597
forelimb function	54613
we	54641
the ventral portion of the CST	54658
the ventral portion	54658
the CST	54681
a similar mechanism	54690
we	54752
functional improvements	54766
the extent	54817
anatomical regeneration and reconnection	54831
descending nerve tract circuitry within the injured rodent spinal cord	54875
descending nerve tract circuitry	54875
the injured rodent spinal cord	54915
Gene therapy combined with OEG transplantation	54947
Gene therapy	54947
OEG transplantation	54974
a significant effect on the maintenance/regeneration of CST fibres	54998
a significant effect	54998
the maintenance/regeneration of CST fibres	55022
the maintenance/regeneration	55022
CST fibres	55054
sparing of spinal cord tissue in general	55070
sparing	55070
spinal cord tissue in general	55081
spinal cord tissue	55081
general	55103
These results	55112
credence to further study of OEG	55131
credence	55131
further study of OEG	55143
further study	55143
OEG	55160
transplantation	55164
combination	55183
long-term secretion of neurotrophic factors , e.g.	55200
long-term secretion	55200
neurotrophic factors	55223
lentiviral vectors	55259
Ruitenberg	55279
et al. , 2002a	55290
et al.	55290
2002a	55298
There	55306
functional axonal regeneration , compensation and axonal plasticity	55367
potential outcomes	55437
spinal cord injuries	55462
Development	55484
more appropriate measures	55499
sensorimotor performance in rodents -LRB- e.g. Metz and Whishaw , 2002 -RRB-	55528
sensorimotor performance	55528
rodents -LRB- e.g. Metz and Whishaw , 2002 -RRB-	55556
rodents	55556
e.g. Metz and Whishaw , 2002	55565
e.g.	55565
Metz and Whishaw	55570
2002	55588
better , more realistic and hopefully more clinically relevant interpretation	55605
functional outcomes	55685
spinal cord injury in these animals	55711
spinal cord injury	55711
these animals	55733
